BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127. [PMID: 21992124 DOI: 10.1056/nejmra1001683] [Cited by in Crossref: 2594] [Cited by in F6Publishing: 1498] [Article Influence: 259.4] [Reference Citation Analysis]
Number Citing Articles
1 Huang DP, Zeng YH, Yuan WQ, Huang XF, Chen SQ, Wang MY, Qiu YJ, Tong GD. Bioinformatics Analyses of Potential miRNA-mRNA Regulatory Axis in HBV-related Hepatocellular Carcinoma. Int J Med Sci 2021;18:335-46. [PMID: 33390802 DOI: 10.7150/ijms.50126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang J, Mao Y, Liu Y, Chen Z, Chen M, Lao X, Li S. Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment. J Gastrointest Surg. 2017;21:1128-1135. [PMID: 28397025 DOI: 10.1007/s11605-017-3420-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
3 Sze KM, Ho DW, Chiu YT, Tsui YM, Chan LK, Lee JM, Chok KS, Chan AC, Tang CN, Tang VW, Lo IL, Yau DT, Cheung TT, Ng IO. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. Hepatology 2021;73:23-40. [PMID: 32170761 DOI: 10.1002/hep.31231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
4 Shimizu D, Kanda M, Sugimoto H, Shibata M, Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol 2017;50:381-6. [PMID: 28101581 DOI: 10.3892/ijo.2017.3833] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
5 Kim JB, Lee S, Kim HR, Park SY, Lee M, Yoon JH, Kim YJ. Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro. Oncol Lett 2018;15:8723-8. [PMID: 29805610 DOI: 10.3892/ol.2018.8441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Carbajo-Pescador S, Steinmetz C, Kashyap A, Lorenz S, Mauriz JL, Heise M, Galle PR, González-Gallego J, Strand S. Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer. 2013;108:442-449. [PMID: 23257900 DOI: 10.1038/bjc.2012.563] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
7 Jariwala N, Rajasekaran D, Srivastava J, Gredler R, Akiel MA, Robertson CL, Emdad L, Fisher PB, Sarkar D. Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review). Int J Oncol 2015;46:465-73. [PMID: 25405367 DOI: 10.3892/ijo.2014.2766] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
8 Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014;41:6575-6582. [PMID: 25091939 DOI: 10.1007/s11033-014-3541-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
9 Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274-1278. [PMID: 22537433 DOI: 10.1053/j.gastro.2012.01.045] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
10 Shen W, Du R, Li J, Luo X, Zhao S, Chang A, Zhou W, Gao R, Luo D, Wang J, Hao N, Liu Y, Chen Y, Luo Y, Sun P, Yang S, Luo N, Xiang R. TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways. Signal Transduct Target Ther 2016;1:16013. [PMID: 29263897 DOI: 10.1038/sigtrans.2016.13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
11 Daecher A, Stanczak M, Liu JB, Zhang J, Du S, Forsberg F, Leeper DB, Eisenbrey JR. Localized microbubble cavitation-based antivascular therapy for improving HCC treatment response to radiotherapy. Cancer Lett 2017;411:100-5. [PMID: 28969964 DOI: 10.1016/j.canlet.2017.09.037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
12 Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol 2018;4:1683-90. [PMID: 30286235 DOI: 10.1001/jamaoncol.2018.4154] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 40.5] [Reference Citation Analysis]
13 Xie R, Xu J, Wen G, Jin H, Liu X, Yang Y, Ji B, Jiang Y, Song P, Dong H, Tuo B. The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J Biol Chem 2014;289:19137-49. [PMID: 24847054 DOI: 10.1074/jbc.M113.540047] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
14 Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol 2019;12:53. [PMID: 31142326 DOI: 10.1186/s13045-019-0739-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 17.5] [Reference Citation Analysis]
15 Wu Z, He L, Wang L, Peng L. Systematically Exploring the Antitumor Mechanisms of Core Chinese Herbs on Hepatocellular Carcinoma: A Computational Study. Evid Based Complement Alternat Med 2020;2020:2396569. [PMID: 33014099 DOI: 10.1155/2020/2396569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ashizawa Y, Kuboki S, Nojima H, Yoshitomi H, Furukawa K, Takayashiki T, Takano S, Miyazaki M, Ohtsuka M. OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma. Hepatol Commun 2019;3:954-70. [PMID: 31304451 DOI: 10.1002/hep4.1361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Ward MP, Spiers JP. Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion. Br J Pharmacol 2017;174:1116-30. [PMID: 28239848 DOI: 10.1111/bph.13759] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
18 Wang J, Wu S, Huang T. Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma. Exp Ther Med 2018;15:5450-6. [PMID: 29904424 DOI: 10.3892/etm.2018.6129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Dogan S, Gurakar A. Liver Transplantation Update: 2014. Euroasian J Hepatogastroenterol 2015;5:98-106. [PMID: 29201702 DOI: 10.5005/jp-journals-10018-1144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Djouder N. Boosting NAD(+) for the prevention and treatment of liver cancer. Mol Cell Oncol 2015;2:e1001199. [PMID: 27308492 DOI: 10.1080/23723556.2014.1001199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
21 Maceyka M, Rohrbach T, Milstien S, Spiegel S. Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma. Handb Exp Pharmacol 2020;259:3-17. [PMID: 31321542 DOI: 10.1007/164_2019_217] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
22 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 153] [Article Influence: 44.0] [Reference Citation Analysis]
23 Liu HT, Huang YC, Cheng SB, Huang YT, Lin PT. Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. Nutr J 2016;15:85. [PMID: 27716246 DOI: 10.1186/s12937-016-0205-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
24 Fouad S, Wells OS, Hill MA, D'Angiolella V. Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment. Front Physiol 2019;10:1144. [PMID: 31632280 DOI: 10.3389/fphys.2019.01144] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
25 Lin Z, Huang W, He Q, Li D, Wang Z, Feng Y, Liu D, Zhang T, Wang Y, Xie M, Ji X, Sun M, Tian D, Xia L. FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter. J Exp Clin Cancer Res 2021;40:50. [PMID: 33522955 DOI: 10.1186/s13046-021-01829-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Hu SJ, Jiang SS, Zhang J, Luo D, Yu B, Yang LY, Zhong HH, Yang MW, Liu LY, Hong FF, Yang SL. Effects of apoptosis on liver aging. World J Clin Cases 2019;7:691-704. [PMID: 30968034 DOI: 10.12998/wjcc.v7.i6.691] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
27 Agioutantis PC, Kotsikoris V, Kolisis FN, Loutrari H. RNA-seq data analysis of stimulated hepatocellular carcinoma cells treated with epigallocatechin gallate and fisetin reveals target genes and action mechanisms. Comput Struct Biotechnol J 2020;18:686-95. [PMID: 32257052 DOI: 10.1016/j.csbj.2020.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci 2019;64:910-7. [DOI: 10.1007/s10620-019-05537-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 43.0] [Reference Citation Analysis]
29 Liu BH, Jobichen C, Chia CSB, Chan THM, Tang JP, Chung TXY, Li J, Poulsen A, Hung AW, Koh-Stenta X, Tan YS, Verma CS, Tan HK, Wu CS, Li F, Hill J, Joy J, Yang H, Chai L, Sivaraman J, Tenen DG. Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide. Proc Natl Acad Sci USA. 2018;115:E7119-E7128. [PMID: 29976840 DOI: 10.1073/pnas.1801253115] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
30 Zhang X, Luo P, Jing W, Zhou H, Liang C, Tu J. circSMAD2 inhibits the epithelial-mesenchymal transition by targeting miR-629 in hepatocellular carcinoma. Onco Targets Ther. 2018;11:2853-2863. [PMID: 29844683 DOI: 10.2147/ott.s158008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
31 O' Doherty J. A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy. J Diagn Imaging Ther 2015;2:1-34. [PMID: 27182449 DOI: 10.17229/jdit.2015-0428-016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
32 Duran A, Hernandez ED, Reina-Campos M, Castilla EA, Subramaniam S, Raghunandan S, Roberts LR, Kisseleva T, Karin M, Diaz-Meco MT, Moscat J. p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer. Cancer Cell. 2016;30:595-609. [PMID: 27728806 DOI: 10.1016/j.ccell.2016.09.004] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 27.5] [Reference Citation Analysis]
33 Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JH, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proc Natl Acad Sci U S A 2020;117:6103-13. [PMID: 32123069 DOI: 10.1073/pnas.1912146117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
34 Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. Int J Mol Sci 2019;20:E605. [PMID: 30704150 DOI: 10.3390/ijms20030605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Yu D, Dong Z, Yao M, Wu W, Yan M, Yan X, Qiu L, Chen J, Sai W, Yao D. Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA. Tumour Biol. 2013;34:661-668. [PMID: 23192642 DOI: 10.1007/s13277-012-0593-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
37 Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015;6:482-9. [PMID: 25874013 DOI: 10.7150/jca.11665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
38 Lam W, Jiang Z, Guan F, Huang X, Hu R, Wang J, Bussom S, Liu SH, Zhao H, Yen Y, Cheng YC. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci Rep 2015;5:9384. [PMID: 25819872 DOI: 10.1038/srep09384] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
39 Chen W, Yang J, Zhang Y, Cai H, Chen X, Sun D. Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. FEBS Open Bio 2019;9:335-47. [PMID: 30761258 DOI: 10.1002/2211-5463.12578] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
40 Tang X, Feng D, Li M, Zhou J, Li X, Zhao D, Hao B, Li D, Ding K. Transcriptomic Analysis of mRNA-lncRNA-miRNA Interactions in Hepatocellular Carcinoma. Sci Rep 2019;9:16096. [PMID: 31695090 DOI: 10.1038/s41598-019-52559-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
41 Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442-5460. [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 70] [Article Influence: 14.5] [Reference Citation Analysis]
42 Zhan Q, Xu JH, Yu YY, Lo Kk E, El-Nezami H, Zeng Z; Felicianna. Human immune repertoire in hepatitis B virus infection. World J Gastroenterol 2021;27:3790-801. [PMID: 34321844 DOI: 10.3748/wjg.v27.i25.3790] [Reference Citation Analysis]
43 Zhang EB, Zhang X, Wang K, Zhang F, Chen TW, Ma N, Ni QZ, Wang YK, Zheng QW, Cao HJ, Xia J, Zhu B, Xu S, Ding X, Wang X, Li Z, Cheng S, Xie D, Li JJ. Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene 2021. [PMID: 34247189 DOI: 10.1038/s41388-021-01934-y] [Reference Citation Analysis]
44 Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer 2015;15:542. [PMID: 26206264 DOI: 10.1186/s12885-015-1562-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
45 Uchino K, Tateishi R, Nakagomi R, Fujiwara N, Minami T, Sato M, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Shibahara J, Shiina S, Koike K. Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One 2018;13:e0200943. [PMID: 30044835 DOI: 10.1371/journal.pone.0200943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, Li MH, Ding ZW, Liu LJ, Jiang TY, Yang JH, Wang HY. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer 2013;109:14-23. [PMID: 23764751 DOI: 10.1038/bjc.2013.293] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
47 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7:1157-1167. [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
48 Li Y, Poppoe F, Chen J, Yu L, Deng F, Luo Q, Xu Y, Cai Y, Shen J. Macrophages Polarized by Expression of ToxoGRA15II Inhibit Growth of Hepatic Carcinoma. Front Immunol 2017;8:137. [PMID: 28243242 DOI: 10.3389/fimmu.2017.00137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, Barajas JM, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 2017;16:312-22. [PMID: 27980102 DOI: 10.1158/1535-7163.MCT-16-0124] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 10.2] [Reference Citation Analysis]
50 Umeda S, Kanda M, Sugimoto H, Tanaka H, Hayashi M, Yamada S, Fujii T, Takami H, Niwa Y, Iwata N, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer 2017;17:610. [PMID: 28863781 DOI: 10.1186/s12885-017-3629-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Chen M, Liu Y, Varley P, Chang Y, He XX, Huang H, Tang D, Lotze MT, Lin J, Tsung A. High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res. 2015;75:1645-1656. [PMID: 25720799 DOI: 10.1158/0008-5472.can-14-2147] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
52 Zhou X, Wen Y, Tian Y, He M, Ke X, Huang Z, He Y, Liu L, Scharf A, Lu M, Zhang G, Deng Y, Yan Y, Mayer MP, Chen X, Zou F. Heat Shock Protein 90α-Dependent B-Cell-2-Associated Transcription Factor 1 Promotes Hepatocellular Carcinoma Proliferation by Regulating MYC Proto-Oncogene c-MYC mRNA Stability. Hepatology 2019;69:1564-81. [PMID: 30015413 DOI: 10.1002/hep.30172] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
53 Jeng JE, Tsai MF, Tsai HR, Chuang LY, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Tsai JF. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Tumour Biol 2014;35:3689-98. [PMID: 24375326 DOI: 10.1007/s13277-013-1488-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol 2016;22:823-32. [PMID: 26811628 DOI: 10.3748/wjg.v22.i2.823] [Cited by in CrossRef: 131] [Cited by in F6Publishing: 115] [Article Influence: 32.8] [Reference Citation Analysis]
55 Lyra-González I, Flores-Fong LE, González-García I, Medina-Preciado D, Armendáriz-Borunda J. MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol 2015;7:1530-40. [PMID: 26085912 DOI: 10.4254/wjh.v7.i11.1530] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
56 Jiang L, Yang YD, Fu L, Xu W, Liu D, Liang Q, Zhang X, Xu L, Guan XY, Wu B, Sung JJ, Yu J. CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget 2014;5:7663-76. [PMID: 25277196 DOI: 10.18632/oncotarget.2288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
57 Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2:367-383. [PMID: 24400224 DOI: 10.1159/000343852] [Cited by in Crossref: 95] [Cited by in F6Publishing: 73] [Article Influence: 13.6] [Reference Citation Analysis]
58 Schotten C, Bechmann LP, Manka P, Theysohn J, Dechêne A, El Fouly A, Barbato F, Neumann U, Radünz S, Sydor S, Heider D, Venerito M, Canbay A, Gerken G, Herrmann K, Wedemeyer H, Best J. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer 2019;8:491-504. [PMID: 31799206 DOI: 10.1159/000501484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 He ZX, Xiang P, Gong JP, Cheng NS, Zhang W. Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review. Ther Clin Risk Manag 2016;12:295-303. [PMID: 26966370 DOI: 10.2147/TCRM.S96760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
60 Yu WB, Rao A, Vu V, Xu L, Rao JY, Wu JX. Management of centrally located hepatocellular carcinoma: Update 2016. World J Hepatol 2017;9:627-34. [PMID: 28539990 DOI: 10.4254/wjh.v9.i13.627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
61 Mittal S, Kanwal F, Ying J, Chung R, Sada YH, Temple S, Davila JA, El-Serag HB. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol 2016;65:1148-54. [PMID: 27476765 DOI: 10.1016/j.jhep.2016.07.025] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 15.4] [Reference Citation Analysis]
62 Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, Lim K, Wu T. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology. 2013;58:1681-1692. [PMID: 23703729 DOI: 10.1002/hep.26514] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 10.8] [Reference Citation Analysis]
63 Hu B, Yan X, Liu F, Zhu C, Zhou H, Chen Y, Liu J, Gu X, Ni R, Zhang T. Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression. Pathol Oncol Res. 2016;22:555-565. [PMID: 26715439 DOI: 10.1007/s12253-015-0038-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
64 Rahim EA, Noh MS, Ngah NA, Suraini MS, Yusof MM. Hepatocellular carcinoma with disseminated skeletal muscle metastasis. Acta Radiol Open 2017;6:2058460117716705. [PMID: 28811928 DOI: 10.1177/2058460117716705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Peng C, Kaščáková S, Chiappini F, Olaya N, Sandt C, Yousef I, Samuel D, Dumas P, Guettier C, Le Naour F. Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. J Transl Med 2016;14:9. [PMID: 26754490 DOI: 10.1186/s12967-016-0763-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
66 Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702-711. [PMID: 23225107 DOI: 10.1007/s11605-012-2087-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
67 Vogl TJ, Gruber-Rouh T. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. Dig Dis Sci 2019;64:959-67. [PMID: 30835030 DOI: 10.1007/s10620-019-05542-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
68 Qu Z, Wu J, Wu J, Ji A, Qiang G, Jiang Y, Jiang C, Ding Y. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:80666-78. [PMID: 29113334 DOI: 10.18632/oncotarget.20881] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
69 Shi HY, Lee KT, Lee HH, Ho WH, Sun DP, Wang JJ, Chiu CC. Comparison of artificial neural network and logistic regression models for predicting in-hospital mortality after primary liver cancer surgery. PLoS One. 2012;7:e35781. [PMID: 22563399 DOI: 10.1371/journal.pone.0035781] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
70 Davis CI, Gu X, Kiefer RM, Ralle M, Gade TP, Brady DC. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics 2020;12:1995-2008. [PMID: 33146201 DOI: 10.1039/d0mt00156b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Moon H, Cho K, Shin S, Kim DY, Han KH, Ro SW. High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. Int J Mol Sci. 2019;20. [PMID: 30700007 DOI: 10.3390/ijms20030581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
72 Lee JH, Suh JH, Choi SY, Kang HJ, Lee HH, Ye BJ, Lee GR, Jung SW, Kim CJ, Lee-Kwon W, Park J, Myung K, Park NH, Kwon HM. Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis. Gut 2019;68:347-58. [PMID: 29420225 DOI: 10.1136/gutjnl-2017-315348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
73 Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett 2019;459:156-67. [PMID: 31181320 DOI: 10.1016/j.canlet.2019.114429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
74 Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64:820-829. [PMID: 25021421 DOI: 10.1136/gutjnl-2013-306228] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 12.3] [Reference Citation Analysis]
75 Liang BY, Gu J, Xiong M, Zhang EL, Zhang ZY, Chen XP, Huang ZY. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Sci Rep 2021;11:16343. [PMID: 34381132 DOI: 10.1038/s41598-021-95835-5] [Reference Citation Analysis]
76 Simão A, Madaleno J, Silva N, Rodrigues F, Caseiro P, Costa JN, Carvalho A. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterol 2015;15:73. [PMID: 26122937 DOI: 10.1186/s12876-015-0307-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
77 Newman NB, Jabbour SK, Hon JD, Berman JJ, Malik D, Carpizo D, Moss RA. Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review. J Clin Exp Hepatol 2015;5:163-6. [PMID: 26155045 DOI: 10.1016/j.jceh.2015.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
78 Yu W, Roy SK, Ma Y, LaVeist TA, Shankar S, Srivastava RK. Higher expression of SATB2 in hepatocellular carcinoma of African Americans determines more aggressive phenotypes than those of Caucasian Americans. J Cell Mol Med 2019;23:7999-8009. [PMID: 31602781 DOI: 10.1111/jcmm.14652] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
79 Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
80 Huang Y, Tan N, Jia D, Jing Y, Wang Q, Li Z, Zhang J, Liu L, Li J, Chen Z, He X. Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer. Tumour Biol 2015;36:9753-61. [PMID: 26156804 DOI: 10.1007/s13277-015-3753-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
81 Du X, Wu L, Ur Rahman MS, Teng X, Teng L, Ye J, Cao J. Promoter Hypomethylation Is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma. Dis Markers 2019;2019:9175215. [PMID: 31558918 DOI: 10.1155/2019/9175215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 Wang YY, Qi LN, Zhong JH, Qin HG, Ye JZ, Lu SD, Ma L, Xiang BD, Li LQ, You XM. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2017;7:42199. [PMID: 28181486 DOI: 10.1038/srep42199] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
83 Korba B, Shetty K, Medvedev A, Viswanathan P, Varghese R, Zhou B, Roy R, Makambi K, Ressom H, Loffredo CA. Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk. J Gen Virol 2015;96:2928-37. [PMID: 26296571 DOI: 10.1099/jgv.0.000219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
84 Ho SY, Hsu CY, Liu PH, Ko CC, Huang YH, Su CW, Lee RC, Hou MC, Huo TI. Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers (Basel) 2020;12:E1130. [PMID: 32366000 DOI: 10.3390/cancers12051130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
85 Koh MY, Gagea M, Sargis T, Lemos R Jr, Grandjean G, Charbono A, Bekiaris V, Sedy J, Kiriakova G, Liu X, Roberts LR, Ware C, Powis G. A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. Hepatology 2016;63:1576-91. [PMID: 26799785 DOI: 10.1002/hep.28468] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
86 Tan S, Zhang M, Shi X, Ding K, Zhao Q, Guo Q, Wang H, Wu Z, Kang Y, Zhu T, Sun J, Zhao X. CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression. J Exp Clin Cancer Res 2021;40:85. [PMID: 33648552 DOI: 10.1186/s13046-021-01884-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Fang F, Song T, Zhang T, Cui Y, Zhang G, Xiong Q. MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways. Oncotarget 2017;8:31745-57. [PMID: 28423650 DOI: 10.18632/oncotarget.15958] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
88 Khalid M, Brisson L, Tariq M, Hao Y, Guibon R, Fromont G, Mortadza SAS, Mousawi F, Manzoor S, Roger S, Jiang LH. Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells. Oncotarget 2017;8:37278-90. [PMID: 28418839 DOI: 10.18632/oncotarget.16191] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
89 Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, Franck S, Lee JM, Ng IO, Cheung TT, Wei X, Liu N, Ji J, Zhao L, Liu Z, Jia HL, Tang ZY, Qin LX, Kloeckner R, Marquardt J, Greten T, Wang XW. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci 2019;15:2654-63. [PMID: 31754337 DOI: 10.7150/ijbs.39534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Jiang H, Zhu Y, Zhou Z, Xu J, Jin S, Xu K, Zhang H, Sun Q, Wang J, Xu J. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma. Cancer Med 2018;7:869-82. [PMID: 29441724 DOI: 10.1002/cam4.1360] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
91 Candia J, Bayarsaikhan E, Tandon M, Budhu A, Forgues M, Tovuu LO, Tudev U, Lack J, Chao A, Chinburen J, Wang XW. The genomic landscape of Mongolian hepatocellular carcinoma. Nat Commun 2020;11:4383. [PMID: 32873799 DOI: 10.1038/s41467-020-18186-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
92 Kang C, Jia X, Liu H. Development and validation of a RNA binding protein gene pair-associated prognostic signature for prediction of overall survival in hepatocellular carcinoma. Biomed Eng Online 2020;19:68. [PMID: 32873282 DOI: 10.1186/s12938-020-00812-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
93 Hlady RA, Zhao X, Pan X, Yang JD, Ahmed F, Antwi SO, Giama NH, Patel T, Roberts LR, Liu C, Robertson KD. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. Theranostics 2019;9:7239-50. [PMID: 31695765 DOI: 10.7150/thno.35573] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
94 El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J 2017;5:227-35. [PMID: 28344790 DOI: 10.1177/2050640616659024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
95 Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019;156:1849-1861.e13. [PMID: 30711629 DOI: 10.1053/j.gastro.2019.01.252] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 23.0] [Reference Citation Analysis]
96 Zhang N, Bi C, Liu L, Dou Y, Tang S, Pang W, Deng H, Song D. IMB-6G, a novel N-substituted sophoridinic acid derivative, induces endoplasmic reticulum stress-mediated apoptosis via activation of IRE1α and PERK signaling. Oncotarget 2016;7:23860-73. [PMID: 27009865 DOI: 10.18632/oncotarget.8184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
97 Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 2016;64:488-500. [PMID: 27015352 DOI: 10.1002/hep.28574] [Cited by in Crossref: 167] [Cited by in F6Publishing: 157] [Article Influence: 33.4] [Reference Citation Analysis]
98 Hsiao CY, Chen PD, Huang KW. A Prospective Assessment of the Diagnostic Value of Contrast-Enhanced Ultrasound, Dynamic Computed Tomography and Magnetic Resonance Imaging for Patients with Small Liver Tumors. J Clin Med 2019;8:E1353. [PMID: 31480576 DOI: 10.3390/jcm8091353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
99 Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, Katchy CA, Lee C, Moore DD, Fu L. Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis. Cancer Cell 2016;30:909-24. [PMID: 27889186 DOI: 10.1016/j.ccell.2016.10.007] [Cited by in Crossref: 190] [Cited by in F6Publishing: 159] [Article Influence: 38.0] [Reference Citation Analysis]
100 Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D. Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. Metabolites. 2012;2:701-716. [PMID: 24957758 DOI: 10.3390/metabo2040701] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
101 Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q, Wang J. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 2015;15:531. [PMID: 26194347 DOI: 10.1186/s12885-015-1541-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 12.3] [Reference Citation Analysis]
102 Farra R, Grassi M, Grassi G, Dapas B. Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World J Gastroenterol 2015;21:8994-9001. [PMID: 26290628 DOI: 10.3748/wjg.v21.i30.8994] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
103 Kim SM, Han JM, Le TT, Sohng JK, Jung HJ. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α. Int J Mol Sci 2020;21:E4043. [PMID: 32516967 DOI: 10.3390/ijms21114043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Guo Y, Peng Y, Gao D, Zhang M, Yang W, Linghu E, Herman JG, Fuks F, Dong G, Guo M. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma. Clin Epigenetics 2017;9:116. [PMID: 29075359 DOI: 10.1186/s13148-017-0412-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
105 Giani A, Cipriani F, Famularo S, Donadon M, Bernasconi DP, Ardito F, Fazio F, Nicolini D, Perri P, Giuffrida M, Pontarolo N, Zanello M, Lai Q, Conci S, Molfino S, Germani P, Pinotti E, Romano M, La Barba G, Ferrari C, Patauner S, Manzoni A, Sciannamea I, Fumagalli L, Troci A, Ferraro V, Floridi A, Memeo R, Crespi M, Chiarelli M, Antonucci A, Zimmitti G, Frena A, Percivale A, Ercolani G, Zanus G, Zago M, Tarchi P, Baiocchi GL, Ruzzenente A, Rossi M, Jovine E, Maestri M, Dalla Valle R, Grazi G, Vivarelli M, Ferrero A, Giuliante F, Torzilli G, Aldrighetti L, Gianotti L, Romano F, Ciulli C, Braga M, Ratti F, Costa G, Razionale F, Russolillo N, Marinelli L, De Peppo V, Cremaschi E, Calabrese F, Larghi Laureiro Z, Lazzari G, Cosola D, Montuori M, Salvador L, Cucchetti A, Franceschi A, Ciola M, Sega V, Calcagno P, Pennacchi L, Tedeschi M. Performance of Comprehensive Complication Index and Clavien-Dindo Complication Scoring System in Liver Surgery for Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 33371419 DOI: 10.3390/cancers12123868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Yin H, Lin Z, Nie S, Wu J, Tan Z, Zhu J, Dai J, Feng Z, Marrero J, Lubman DM. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res. 2014;13:2887-2896. [PMID: 24799124 DOI: 10.1021/pr500043k] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
107 Tummala KS, Djouder N. Oncogene-induced NAD(+) depletion in tumorigenesis. Oncoscience 2015;2:318-9. [PMID: 26097866 DOI: 10.18632/oncoscience.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
108 Molina-Sánchez P, Lujambio A. Iron overload and liver cancer. J Exp Med 2019;216:723-4. [PMID: 30886060 DOI: 10.1084/jem.20190257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Soto-Gutierrez A, Gough A, Vernetti LA, Taylor DL, Monga SP. Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems. Exp Biol Med (Maywood). 2017;242:1605-1616. [PMID: 28467181 DOI: 10.1177/1535370217707731] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
110 Kataoka J, Shiraha H, Horiguchi S, Sawahara H, Uchida D, Nagahara T, Iwamuro M, Morimoto H, Takeuchi Y, Kuwaki K, Onishi H, Nakamura S, Takaki A, Nouso K, Yagi T, Yamamoto K, Okada H. Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma. Oncol Rep 2016;35:2576-82. [PMID: 26985715 DOI: 10.3892/or.2016.4681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
111 Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res 2016;35:126. [PMID: 27514687 DOI: 10.1186/s13046-016-0402-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
112 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl 2018;24:1346-56. [PMID: 30067889 DOI: 10.1002/lt.25317] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
113 King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64:1296-1302. [PMID: 25143343 DOI: 10.1136/gutjnl-2014-307862] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
114 Xu W, Guo W, Lu P, Ma D, Liu L, Yu F. Identification of an autophagy-related gene signature predicting overall survival for hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203231. [PMID: 33351066 DOI: 10.1042/BSR20203231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Yuan B, Liang Y, Wang D, Luo F. MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. Cancer Sci 2015;106:819-24. [PMID: 25940592 DOI: 10.1111/cas.12688] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
116 Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015;7:1742-54. [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
117 Tovuu LO, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Arakawa Y, Mori H, Hanaoka J, Kanamoto M, Sugimoto K, Saito Y, Yamada S, Asanoma M, Shimada M. The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. Int J Clin Oncol 2014;19:622-8. [PMID: 23893130 DOI: 10.1007/s10147-013-0593-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
118 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 229] [Article Influence: 83.6] [Reference Citation Analysis]
119 Diaz G, Engle RE, Tice A, Melis M, Montenegro S, Rodriguez-Canales J, Hanson J, Emmert-Buck MR, Bock KW, Moore IN, Zamboni F, Govindarajan S, Kleiner DE, Farci P. Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma. Mol Cancer Res. 2018;16:1406-1419. [PMID: 29858376 DOI: 10.1158/1541-7786.mcr-18-0012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
120 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-47. [PMID: 28789390 DOI: 10.3892/ol.2017.6287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
121 Qi X, Zhao Y, Li H, Guo X, Han G. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget 2016;7:34703-51. [PMID: 27167195 DOI: 10.18632/oncotarget.9157] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
122 Fernández-Rodríguez CM, Gutiérrez-García ML. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther. 2014;5:175-182. [PMID: 25133046 DOI: 10.4292/wjgpt.v5.i3.175] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
123 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
124 Wen X, Reynolds L, Mulik RS, Kim SY, Van Treuren T, Nguyen LH, Zhu H, Corbin IR. Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. Gastroenterology 2016;150:488-98. [PMID: 26484708 DOI: 10.1053/j.gastro.2015.10.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
125 Lv X, Ye G, Zhang X, Huang T. p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA). Medicine (Baltimore) 2017;96:e8106. [PMID: 28930859 DOI: 10.1097/MD.0000000000008106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
126 Xiao J, Zhao Y, Varghese RS, Zhou B, Di Poto C, Zhang L, Tadesse MG, Ziada DH, Shetty K, Ressom HW. Evaluation of metabolite biomarkers for hepatocellular carcinoma through stratified analysis by gender, race, and alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev 2014;23:64-72. [PMID: 24186894 DOI: 10.1158/1055-9965.EPI-13-0327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
127 Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol 2017;23:239-48. [PMID: 28706177 DOI: 10.3350/cmh.2017.0008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
128 Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 2018;41:819-27. [PMID: 29423829 DOI: 10.1007/s10545-018-0142-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
129 Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sällberg M. Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. PLoS One 2015;10:e0128466. [PMID: 26030283 DOI: 10.1371/journal.pone.0128466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Ait-Oudhia S, Mager DE, Pokuri V, Tomaszewski G, Groman A, Zagst P, Fetterly G, Iyer R. Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. CPT Pharmacometrics Syst Pharmacol 2016;5:297-304. [PMID: 27300260 DOI: 10.1002/psp4.12084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
131 Wan G, Gao F, Chen J, Li Y, Geng M, Sun L, Liu Y, Liu H, Yang X, Wang R. Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2017;17:91. [PMID: 28143427 DOI: 10.1186/s12885-017-3062-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
132 Mello T, Materozzi M, Galli A. PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR Res 2016;2016:7403230. [PMID: 28115925 DOI: 10.1155/2016/7403230] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
133 Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget. 2012;3:940-953. [PMID: 22964488 DOI: 10.18632/oncotarget.623] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
134 Xiang X, Zhong JH, Wang YY, You XM, Ma L, Xiang BD, Li LQ. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clin Transl Oncol 2017;19:891-7. [PMID: 28160206 DOI: 10.1007/s12094-017-1621-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
135 Li L, Jia L, Ding Y. Upregulation of miR-375 inhibits human liver cancer cell growth by modulating cell proliferation and apoptosis via targeting ErbB2. Oncol Lett. 2018;16:3319-3326. [PMID: 30127930 DOI: 10.3892/ol.2018.9011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
136 Aberra FB, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160. [PMID: 23111632 DOI: 10.1007/s10620-012-2461-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
137 Ma L, Deng C. Identification of a novel four-lncRNA signature as a prognostic indicator in cirrhotic hepatocellular carcinoma. PeerJ 2019;7:e7413. [PMID: 31396449 DOI: 10.7717/peerj.7413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
138 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
139 Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:1886-1893.e5. [PMID: 30557738 DOI: 10.1016/j.cgh.2018.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
140 Youn SY, Kim DH, Choi JI, Choi MH, Kim B, Shin YR, Oh SN, Rha SE. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI. Korean J Radiol 2021;22:1289-99. [PMID: 34047507 DOI: 10.3348/kjr.2020.1394] [Reference Citation Analysis]
141 Kril LM, Vilchez V, Jiang J, Turcios L, Chen C, Sviripa VM, Zhang W, Liu C, Spear B, Watt DS. N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and β-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells. Bioorg Med Chem Lett. 2015;25:3897-3899. [PMID: 26243371 DOI: 10.1016/j.bmcl.2015.07.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
142 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 259] [Article Influence: 44.8] [Reference Citation Analysis]
143 Salami AC, Barden GM, Castillo DL, Hanna M, Petersen NJ, Davila JA, Naik AD, Anaya DA. Establishment of a Regional Virtual Tumor Board Program to Improve the Process of Care for Patients With Hepatocellular Carcinoma. J Oncol Pract 2015;11:e66-74. [PMID: 25466708 DOI: 10.1200/JOP.2014.000679] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
144 Park HJ, Choi BI, Lee ES, Park SB, Lee JB. How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis. Liver Cancer 2017;6:189-203. [PMID: 28626731 DOI: 10.1159/000455949] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
145 Joliat GR, Allemann P, Labgaa I, Demartines N, Halkic N. Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402:737-744. [PMID: 28497194 DOI: 10.1007/s00423-017-1582-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
146 Lou G, Chen L, Xia C, Wang W, Qi J, Li A, Zhao L, Chen Z, Zheng M, Liu Y. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J Exp Clin Cancer Res. 2020;39:4. [PMID: 31898515 DOI: 10.1186/s13046-019-1512-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 36.0] [Reference Citation Analysis]
147 Mu XM, Wang W, Jiang YY, Feng J. Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. Int J Environ Res Public Health 2020;17:E3108. [PMID: 32365650 DOI: 10.3390/ijerph17093108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Liu Y, Li Y, Wang R, Qin S, Liu J, Su F, Yang Y, Zhao F, Wang Z, Wu Q. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J Exp Clin Cancer Res. 2016;35:19. [PMID: 26817584 DOI: 10.1186/s13046-016-0296-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
149 Li C, Wu X, Zhang H, Yang G, Hao M, Sheng S, Sun Y, Long J, Hu C, Sun X, Li L, Zheng J. A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis. Tumour Biol 2015;36:1739-45. [PMID: 25374064 DOI: 10.1007/s13277-014-2775-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
150 Van Tong H, Hoan NX, Binh MT, Quyen DT, Meyer CG, Song LH, Toan NL, Velavan TP. Interferon-stimulated gene 20 kDa protein serum levels and clinical outcome of hepatitis B virus-related liver diseases. Oncotarget 2018;9:27858-71. [PMID: 29963243 DOI: 10.18632/oncotarget.25559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Li C, Huang Z, Zhu L, Yu X, Gao T, Feng J, Hong H, Yin H, Zhou T, Qi W, Yang Z, Liu C, Yang X, Gao G. The contrary intracellular and extracellular functions of PEDF in HCC development. Cell Death Dis 2019;10:742. [PMID: 31582735 DOI: 10.1038/s41419-019-1976-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
152 Bartucci M, Hussein MS, Huselid E, Flaherty K, Patrizii M, Laddha SV, Kui C, Bigos RA, Gilleran JA, El Ansary MMS, Awad MAM, Kimball SD, Augeri DJ, Sabaawy HE. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Target Oncol 2017;12:449-62. [PMID: 28589491 DOI: 10.1007/s11523-017-0501-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
153 Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, Bang MH, Binh MT, Ky TD, Tung NL, Thinh NT, Sang VV, Thao LTP, Bock CT, Velavan TP, Meyer CG, Song LH, Toan NL. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081. [PMID: 29672637 DOI: 10.1371/journal.pone.0196081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
154 Yan PG, Wang RY, Zhang J, Cong WM, Dong H, Yu HY, Lau WY, Wu MC, Zhou WP. Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients-a Retrospective Study. J Gastrointest Surg 2018;22:872-83. [PMID: 29313290 DOI: 10.1007/s11605-017-3638-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
155 Ho CM, Hu RH, Lee PH, Wu YM, Ho MC. Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size. Medicine (Baltimore) 2014;93:e203. [PMID: 25501076 DOI: 10.1097/MD.0000000000000203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
156 Wang JL, Yang MY, Xiao S, Sun B, Li YM, Yang LY. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling. J Exp Clin Cancer Res 2018;37:45. [PMID: 29506567 DOI: 10.1186/s13046-018-0720-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
157 Ho CM, Wakabayashi G, Nitta H, Takahashi M, Takahara T, Ito N, Hasegawa Y. Total laparoscopic limited anatomical resection for centrally located hepatocellular carcinoma in cirrhotic liver. Surg Endosc. 2013;27:1820-1825. [PMID: 23233006 DOI: 10.1007/s00464-012-2624-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
158 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer. 2017;8:152-161. [PMID: 28243319 DOI: 10.7150/jca.16523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
159 Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122:2871-2883. [PMID: 22820288 DOI: 10.1172/jci63539] [Cited by in Crossref: 532] [Cited by in F6Publishing: 313] [Article Influence: 59.1] [Reference Citation Analysis]
160 Chiang CH, Huang KC. Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:7213-7216. [PMID: 24966591 DOI: 10.3748/wjg.v20.i23.7213] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
161 Baffy G. Decoding multifocal hepatocellular carcinoma: an opportune pursuit. Hepatobiliary Surg Nutr 2015;4:206-10. [PMID: 26151061 DOI: 10.3978/j.issn.2304-3881.2014.12.05] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
162 Chen Q, Yin D, Zhang Y, Yu L, Li XD, Zhou ZJ, Zhou SL, Gao DM, Hu J, Jin C, Wang Z, Shi YH, Cao Y, Fan J, Dai Z, Zhou J. MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. Cell Death Dis 2017;8:e2906. [PMID: 28661477 DOI: 10.1038/cddis.2017.142] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
163 Kovač U, Skubic C, Bohinc L, Rozman D, Režen T. Oxysterols and Gastrointestinal Cancers Around the Clock. Front Endocrinol (Lausanne) 2019;10:483. [PMID: 31379749 DOI: 10.3389/fendo.2019.00483] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
164 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
165 Chhonker SK, Rawat D, Koiri RK. Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma. Mol Cell Biochem 2021;476:1195-209. [PMID: 33216253 DOI: 10.1007/s11010-020-03982-6] [Reference Citation Analysis]
166 Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y, Jiang C, Ding Y. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int 2014;2014:764981. [PMID: 25057499 DOI: 10.1155/2014/764981] [Cited by in Crossref: 13] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
167 Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018;16:955-64. [PMID: 29175528 DOI: 10.1016/j.cgh.2017.11.037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
168 Azumi M, Suda T, Terai S, Akazawa K. Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study. Intern Med 2017;56:1001-7. [PMID: 28458303 DOI: 10.2169/internalmedicine.56.7278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Cao L, Li WJ, Yang JH, Wang Y, Hua ZJ, Liu D, Chen YQ, Zhang HM, Zhang R, Zhao JS, Cheng SJ, Zhang Q. Inflammatory cytokine-induced expression of MASTL is involved in hepatocarcinogenesis by regulating cell cycle progression. Oncol Lett 2019;17:3163-72. [PMID: 30867746 DOI: 10.3892/ol.2019.9983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
170 Wang ST, Huang SW, Liu KT, Lee TY, Shieh JJ, Wu CY. Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway. Cell Death Discov 2020;6:17. [PMID: 32257389 DOI: 10.1038/s41420-020-0252-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
171 Simmons OL, Feng Y, Parikh ND, Singal AG. Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2019;17:766-73. [PMID: 30056183 DOI: 10.1016/j.cgh.2018.07.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
172 Gray SH, White JA, Li P, Kilgore ML, Redden DT, Abdel Aal AK, Simpson HN, McGuire B, Eckhoff DE, Dubay DA. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. J Vasc Interv Radiol 2017;28:231-237.e2. [PMID: 27939085 DOI: 10.1016/j.jvir.2016.09.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
173 Feng YM, Feng CW, Chen SY, Hsieh HY, Chen YH, Hsu CD. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer 2015;15:134. [PMID: 25886177 DOI: 10.1186/s12885-015-1137-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
174 Fitian AI, Cabrera R. Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol. 2017;9:1-17. [PMID: 28105254 DOI: 10.4254/wjh.v9.i1.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
175 Qian F, Hu Q, Tian Y, Wu J, Li D, Tao M, Qin L, Shen B, Xie Y. ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis. Int J Biol Sci 2019;15:369-85. [PMID: 30745827 DOI: 10.7150/ijbs.28422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
176 Bimonte S, Leongito M, Piccirillo M, de Angelis C, Pivonello C, Granata V, Izzo F. Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment. Infect Agent Cancer 2016;11:38. [PMID: 27525037 DOI: 10.1186/s13027-016-0082-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
177 Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G, Durazo FA, El-Kabany MM. Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. J Clin Transl Hepatol. 2017;5:43-49. [PMID: 28507926 DOI: 10.14218/jcth.2016.00057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
178 Choi JH, Hwang S, Lee YJ, Kim KH, Ko GY, Gwon DI, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Lee SG. Prognostic effect of preoperative sequential transcatheter arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2015;19:59-65. [PMID: 26155278 DOI: 10.14701/kjhbps.2015.19.2.59] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
179 Shu G, Zhang L, Jiang S, Cheng Z, Wang G, Huang X, Yang X. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction. Oncotarget 2016;7:40285-96. [PMID: 27244888 DOI: 10.18632/oncotarget.9603] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
180 Wang JH, Zhong XP, Zhang YF, Wu XL, Li SH, Jian PE, Ling YH, Shi M, Chen MS, Wei W, Guo RP. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis 2017;8:e3043. [PMID: 28880268 DOI: 10.1038/cddis.2017.428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
181 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
182 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
183 Nagy LI, Molnár E, Kanizsai I, Madácsi R, Ózsvári B, Fehér LZ, Fábián G, Marton A, Vizler C, Ayaydin F, Kitajka K, Hackler L Jr, Mátés L, Deák F, Kiss I, Puskás LG. Lipid droplet binding thalidomide analogs activate endoplasmic reticulum stress and suppress hepatocellular carcinoma in a chemically induced transgenic mouse model. Lipids Health Dis 2013;12:175. [PMID: 24268070 DOI: 10.1186/1476-511X-12-175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
184 Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat 2019;51:510-8. [PMID: 29898591 DOI: 10.4143/crt.2018.226] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
185 AbouAitah K, Swiderska-Sroda A, Farghali AA, Wojnarowicz J, Stefanek A, Gierlotka S, Opalinska A, Allayeh AK, Ciach T, Lojkowski W. Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action. Oncotarget 2018;9:26466-90. [PMID: 29899871 DOI: 10.18632/oncotarget.25470] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
186 Akiel M, Rajasekaran D, Gredler R, Siddiq A, Srivastava J, Robertson C, Jariwala NH, Fisher PB, Sarkar D. Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:9-19. [PMID: 27508172 DOI: 10.2147/JHC.S44460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Beal EW, Tumin D, Kabir A, Moris D, Zhang XF, Chakedis J, Washburn K, Black S, Schmidt CM, Pawlik TM. Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA. World J Surg. 2018;42:835-840. [PMID: 28879603 DOI: 10.1007/s00268-017-4194-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
188 Goldberg DS, Lewis JD, Halpern SD, Weiner MG, Lo Re V 3rd. Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf 2013;22:103-7. [PMID: 23124932 DOI: 10.1002/pds.3367] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
189 Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7:72343-72355. [PMID: 27579537 DOI: 10.18632/oncotarget.11644] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
190 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019;25:2416-29. [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
191 Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transpl 2019;25:369-79. [PMID: 30582779 DOI: 10.1002/lt.25398] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
192 Tchatalbachev VV, Kirkpatrick DL, Duff DJ, Travis MD. Seeding of the rectus sheath with hepatocellular carcinoma after image guided percutaneous liver biopsy using coaxial biopsy needle system. J Radiol Case Rep 2015;9:18-25. [PMID: 25926917 DOI: 10.3941/jrcr.v9i1.1887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
193 Ji Z, Meng G, Huang D, Yue X, Wang B. NMFBFS: A NMF-Based Feature Selection Method in Identifying Pivotal Clinical Symptoms of Hepatocellular Carcinoma. Comput Math Methods Med 2015;2015:846942. [PMID: 26579207 DOI: 10.1155/2015/846942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
194 Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr 2016;5:415-21. [PMID: 27826556 DOI: 10.21037/hbsn.2016.08.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
195 Su YH, Lin SY, Song W, Jain S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn. 2014;14:803-817. [PMID: 25098554 DOI: 10.1586/14737159.2014.946908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
196 Mixson-Hayden T, Lee D, Ganova-Raeva L, Drobeniuc J, Stauffer WM, Teshale E, Kamili S. Hepatitis B virus and hepatitis C virus infections in United States-bound refugees from Asia and Africa. Am J Trop Med Hyg. 2014;90:1014-1020. [PMID: 24732462 DOI: 10.4269/ajtmh.14-0068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
197 Mo Z, Liu D, Rong D, Zhang S. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:611058. [PMID: 33679749 DOI: 10.3389/fimmu.2021.611058] [Reference Citation Analysis]
198 Zeng JD, Zhang N, Zhao GJ, Xu LX, Yang Y, Xu XY, Chen MK, Wang HY, Zheng SX, Li XX. MT1G is Silenced by DNA Methylation and Contributes to the Pathogenesis of Hepatocellular Carcinoma. J Cancer 2018;9:2807-16. [PMID: 30123349 DOI: 10.7150/jca.25680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
199 Webb GJ, Wright KV, Harrod EC, Gorard DA, Collier JD, Evans AK. Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does α-fetoprotein still have a role? Clin Med (Lond) 2015;15:139-44. [PMID: 25824065 DOI: 10.7861/clinmedicine.15-2-139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
200 McKillop IH, Schrum LW, Thompson KJ. Role of alcohol in the development and progression of hepatocellular carcinoma. Hepat Oncol 2016;3:29-43. [PMID: 30191025 DOI: 10.2217/hep.15.40] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
201 Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford). 2012;14:741-745. [PMID: 23043662 DOI: 10.1111/j.1477-2574.2012.00507.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
202 Tang H, Zhang J, Yu Z, Ye L, Li K, Ding F, Feng X, Meng W. Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma. Technol Cancer Res Treat 2017;16:1136-49. [PMID: 29332449 DOI: 10.1177/1533034617735931] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
203 Wang T, Zhang KH, Hu PP, Wan QS, Han FL, Zhou JM, Huang DQ, Lv NH. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases. Oncotarget 2017;8:97758-68. [PMID: 29228649 DOI: 10.18632/oncotarget.22050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
204 Pelosof L, Lemery S, Casak S, Jiang X, Rodriguez L, Pierre V, Bi Y, Liu J, Zirkelbach JF, Patel A, Goldberg KB, McKee AE, Keegan P, Pazdur R. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. Oncologist 2018;23:496-500. [PMID: 29386313 DOI: 10.1634/theoncologist.2017-0422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
205 Akiel MA, Santhekadur PK, Mendoza RG, Siddiq A, Fisher PB, Sarkar D. Tetraspanin 8 mediates AEG-1-induced invasion and metastasis in hepatocellular carcinoma cells. FEBS Lett 2016;590:2700-8. [PMID: 27339400 DOI: 10.1002/1873-3468.12268] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
206 Chen XP, Long X, Jia WL, Wu HJ, Zhao J, Liang HF, Laurence A, Zhu J, Dong D, Chen Y, Lin L, Xia YD, Li WY, Li GB, Zhao ZK, Wu K, Hou Y, Yu JJ, Xiao W, Wang GP, Zhu PC, Chen W, Bai MZ, Jian YX, Kristiansen K, Chen Q. Viral integration drives multifocal HCC during the occult HBV infection. J Exp Clin Cancer Res 2019;38:261. [PMID: 31200735 DOI: 10.1186/s13046-019-1273-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
207 Jiang DK, Ma XP, Wu X, Peng L, Yin J, Dan Y, Huang HX, Ding DL, Zhang LY, Shi Z. Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis. Sci Rep. 2015;5:16278. [PMID: 26538132 DOI: 10.1038/srep16278] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
208 Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7:267. [PMID: 31627733 DOI: 10.1186/s40425-019-0749-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 19.0] [Reference Citation Analysis]
209 de Oliveira S, Houseright RA, Graves AL, Golenberg N, Korte BG, Miskolci V, Huttenlocher A. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019;70:710-721. [PMID: 30572006 DOI: 10.1016/j.jhep.2018.11.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
210 Li J, Yu Z, Zhu Q, Tao C, Xu Q. hsa_circ_102559 Acts as the Sponge of miR-130a-5p to Promote Hepatocellular Carcinoma Progression Through Regulation of ANXA2. Cell Transplant 2020;29:963689720968748. [PMID: 33121269 DOI: 10.1177/0963689720968748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Cao MT, Liu HF, Liu ZG, Xiao P, Chen JJ, Tan Y, Jiang XX, Jiang ZC, Qiu Y, Huang HJ, Zhang QG, Jiang GM. Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF-β1-induced epithelial-mesenchymal transitions in hepatoma cells. Oncotarget 2017;8:108498-508. [PMID: 29312546 DOI: 10.18632/oncotarget.22590] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
212 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4160. [PMID: 27472685 DOI: 10.1097/MD.0000000000004160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
213 Hanley KL, Feng GS. A new VETC in hepatocellular carcinoma metastasis. Hepatology 2015;62:343-5. [PMID: 25902918 DOI: 10.1002/hep.27860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
214 Zhang Y, Petropoulos S, Liu J, Cheishvili D, Zhou R, Dymov S, Li K, Li N, Szyf M. The signature of liver cancer in immune cells DNA methylation. Clin Epigenetics 2018;10:8. [PMID: 29375724 DOI: 10.1186/s13148-017-0436-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
215 Kao WY, Hwang CY, Su CW, Chang YT, Luo JC, Hou MC, Lin HC, Lee FY, Wu JC. Risk of hepato-biliary cancer after cholecystectomy: a nationwide cohort study. J Gastrointest Surg 2013;17:345-51. [PMID: 23188223 DOI: 10.1007/s11605-012-2090-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
216 Wang S, Lv Y, Zhou Y, Ling J, Wang H, Gu D, Wang C, Qin W, Zheng X, Jin H. Acidic extracellular pH induces autophagy to promote anoikis resistance of hepatocellular carcinoma cells via downregulation of miR-3663-3p. J Cancer 2021;12:3418-26. [PMID: 33995620 DOI: 10.7150/jca.51849] [Reference Citation Analysis]
217 Song J, Zhao Z, Fan X, Chen M, Cheng X, Zhang D, Wu F, Ying X, Ji J. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo. Oncotarget 2016;7:70504-15. [PMID: 27655700 DOI: 10.18632/oncotarget.12041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
218 Dai QS, Gu HL, Ye S, Zhang YJ, Lin XJ, Lau WY, Peng ZW, Chen MS. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol. 2014;2:1047-1054. [PMID: 25279196 DOI: 10.3892/mco.2014.391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
219 Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. Cancer Med 2019;8:2646-53. [PMID: 30900818 DOI: 10.1002/cam4.2061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
220 Baker EH, Thompson K, McKillop IH, Cochran A, Kirks R, Vrochides D, Martinie JB, Swan RZ, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients. J Gastrointest Oncol. 2017;8:337-346. [PMID: 28480072 DOI: 10.21037/jgo.2016.09.06] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
221 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
222 Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A, Iwama A, Yokosuka O. Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol. 2015;7:2020-2028. [PMID: 26261691 DOI: 10.4254/wjh.v7.i16.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
223 Sui CJ, Zhou YM, Shen WF, Dai BH, Lu JJ, Zhang MF, Yang JM. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429. J Mol Med (Berl). 2016;94:1281-1296. [PMID: 27380494 DOI: 10.1007/s00109-016-1442-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
224 Ueno M, Hayami S, Tani M, Kawai M, Hirono S, Yamaue H. Recent trends in hepatectomy for elderly patients with hepatocellular carcinoma. Surg Today 2014;44:1651-9. [DOI: 10.1007/s00595-013-0739-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
225 Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, Zhang CZ, Yun JP. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways. Mol Oncol 2020;14:373-86. [PMID: 31670863 DOI: 10.1002/1878-0261.12593] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
226 Wang X, Liu Y, Qin Q, Zheng T. Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin. Biosci Rep 2020;40:BSR20200071. [PMID: 32039450 DOI: 10.1042/BSR20200071] [Reference Citation Analysis]
227 Schoenberg MB, Bucher JN, Vater A, Bazhin AV, Hao J, Guba MO, Angele MK, Werner J, Rentsch M. Resection or Transplant in Early Hepatocellular Carcinoma. Dtsch Arztebl Int 2017;114:519-26. [PMID: 28835324 DOI: 10.3238/arztebl.2017.0519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
228 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
229 Qu J, Yang J, Chen M, Cui L, Wang T, Gao W, Tian J, Wei R. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis. Pak J Med Sci. 2019;35:1466-1471. [PMID: 31489028 DOI: 10.12669/pjms.35.5.685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
230 Teng Y, Litchfield LM, Ivanova MM, Prough RA, Clark BJ, Klinge CM. Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor. Mol Cell Endocrinol 2014;392:23-36. [PMID: 24845419 DOI: 10.1016/j.mce.2014.05.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
231 Jin YJ, Byun S, Han S, Chamberlin J, Kim D, Kim MJ, Lee Y. Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors. BMC Med Genomics 2019;12:175. [PMID: 31856847 DOI: 10.1186/s12920-019-0635-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
232 Nia AM, Chen T, Barnette BL, Khanipov K, Ullrich RL, Bhavnani SK, Emmett MR. Efficient identification of multiple pathways: RNA-Seq analysis of livers from 56Fe ion irradiated mice. BMC Bioinformatics 2020;21:118. [PMID: 32192433 DOI: 10.1186/s12859-020-3446-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
233 Zhang L, Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zhao XM. A microRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma. Oncotarget 2016;7:3587-98. [PMID: 26657296 DOI: 10.18632/oncotarget.6534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
234 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
235 Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH, Xu GL, Ma JL, Zhong W, Jia WD. Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. 2014;31:786. [PMID: 24297309 DOI: 10.1007/s12032-013-0786-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
236 Zamboni CG, Kozielski KL, Vaughan HJ, Nakata MM, Kim J, Higgins LJ, Pomper MG, Green JJ. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 2017;263:18-28. [PMID: 28351668 DOI: 10.1016/j.jconrel.2017.03.384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
237 Yin F, Sharen G, Yuan F, Peng Y, Chen R, Zhou X, Wei H, Li B, Jing W, Zhao J. TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway. Oncogenesis 2017;6:e347. [PMID: 28604762 DOI: 10.1038/oncsis.2017.49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
238 Nagai N, Kudo Y, Aki D, Nakagawa H, Taniguchi K. Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging. Int J Mol Sci 2021;22:2238. [PMID: 33668122 DOI: 10.3390/ijms22052238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
239 Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut. 2016;65:1522-1534. [PMID: 26941395 DOI: 10.1136/gutjnl-2015-310625] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 20.4] [Reference Citation Analysis]
240 Mao M, Wang X, Sheng H, Liu Y, Zhang L, Dai S, Chi PD. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients. BMC Cancer 2018;18:1178. [PMID: 30486825 DOI: 10.1186/s12885-018-5028-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
241 Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J, Geng M. Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology 2019;69:573-86. [PMID: 29356025 DOI: 10.1002/hep.29792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
242 Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist 2016;21:1113-20. [PMID: 27185615 DOI: 10.1634/theoncologist.2015-0478] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 12.8] [Reference Citation Analysis]
243 Chen Y, Zhang F, Zhao Y, He K, Zheng X, Pan Y, Shao D, Shang P, Yang Y, Zhang D, Xie Y, Yao X, Chen L, Li J, Zhang X. Obesity-associated miR-27a upregulation promotes hepatocellular carcinoma metastasis through suppressing SFRP1. Onco Targets Ther 2018;11:3281-92. [PMID: 29910623 DOI: 10.2147/OTT.S162978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
244 Nault JC. Molecular Determinants of Prognosis in Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:31-6. [PMID: 26357615 DOI: 10.14218/JCTH.2013.00029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
245 Duan X, Zhao G, Han X, Ren J, Li H, Chen P, Wang M, Ju S. Arsenic trioxide-loaded CalliSpheres: In vitro study of drug release and antitumor activity, and in vivo study of pharmacokinetics, treatment efficacy and safety in liver cancer. Oncol Rep 2021;46:124. [PMID: 33982781 DOI: 10.3892/or.2021.8075] [Reference Citation Analysis]
246 Shehta A, Farouk A, Fouad A, Aboelenin A, Elghawalby AN, Said R, Elshobary M, El Nakeeb A. Post-hepatectomy liver failure after hepatic resection for hepatocellular carcinoma: a single center experience. Langenbecks Arch Surg 2021;406:87-98. [PMID: 32778915 DOI: 10.1007/s00423-020-01956-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Zhang L, Chen J, Yong J, Qiao L, Xu L, Liu C. An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:384. [PMID: 31477177 DOI: 10.1186/s13046-019-1382-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
248 Zhang SH, Wang CJ, Shi L, Li XH, Zhou J, Song LB, Liao WT. High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma. PLoS One. 2013;8:e64709. [PMID: 23840303 DOI: 10.1371/journal.pone.0064709] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
249 Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3:e003265. [PMID: 23945731 DOI: 10.1136/bmjopen-2013-003265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
250 McLoughlin MR, Orlicky DJ, Prigge JR, Krishna P, Talago EA, Cavigli IR, Eriksson S, Miller CG, Kundert JA, Sayin VI, Sabol RA, Heinemann J, Brandenberger LO, Iverson SV, Bothner B, Papagiannakopoulos T, Shearn CT, Arnér ESJ, Schmidt EE. TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy. Proc Natl Acad Sci U S A 2019;116:11408-17. [PMID: 31097586 DOI: 10.1073/pnas.1903244116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
251 Uranbileg B, Kurano M, Sato M, Ikeda H, Ishizawa T, Hasegawa K, Kokudo N, Yatomi Y. Possible involvement of PS-PLA1 and lysophosphatidylserine receptor (LPS1) in hepatocellular carcinoma. Sci Rep 2020;10:2659. [PMID: 32060356 DOI: 10.1038/s41598-020-59590-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
252 Sai W, Wang L, Zheng W, Yang J, Pan L, Cai Y, Qiu L, Zhang H, Wu W, Yao D. Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepat Mon. 2015;15:e32918. [PMID: 26977166 DOI: 10.5812/hepatmon.32918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
253 Antwi SO, Van Houten HK, Sangaralingham LR, Patel T. Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C. Cancer Prev Res (Phila) 2019;12:891-902. [PMID: 31451519 DOI: 10.1158/1940-6207.CAPR-19-0162] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
254 Zhao J, Yang Z, Tu M, Meng W, Gao H, Li MD, Li L. Correlation Between Prognostic Biomarker SLC1A5 and Immune Infiltrates in Various Types of Cancers Including Hepatocellular Carcinoma. Front Oncol 2021;11:608641. [PMID: 34367941 DOI: 10.3389/fonc.2021.608641] [Reference Citation Analysis]
255 Tanabe KK, Chiocca EA. "Infectious" optimism for treatment of hepatocellular carcinoma. Mol Ther 2013;21:722-4. [PMID: 23542566 DOI: 10.1038/mt.2013.47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
256 Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev Res (Phila) 2015;8:864-72. [PMID: 26130251 DOI: 10.1158/1940-6207.CAPR-15-0029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
257 Hwang IC, Chang J, Kim K, Park SM. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci Rep 2018;8:4968. [PMID: 29563592 DOI: 10.1038/s41598-018-23343-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
258 An HM, Xue YF, Shen YL, Du Q, Hu B. Sodium valproate induces cell senescence in human hepatocarcinoma cells. Molecules 2013;18:14935-47. [PMID: 24304587 DOI: 10.3390/molecules181214935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
259 Nakagawa H. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. World J Hepatol. 2015;7:2110-2118. [PMID: 26301053 DOI: 10.4254/wjh.v7.i17.2110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
260 Mima K, Hayashi H, Kuroki H, Nakagawa S, Okabe H, Chikamoto A, Watanabe M, Beppu T, Baba H. Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-β signaling. Oncol Lett. 2013;5:149-154. [PMID: 23255911 DOI: 10.3892/ol.2012.954] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
261 Chen Y, Huang Z, Chen X, Ye H. Activation of the Toll‑like receptor 2 signaling pathway inhibits the proliferation of HCC cells in vitro. Oncol Rep 2019;42:2267-78. [PMID: 31578587 DOI: 10.3892/or.2019.7340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
262 Chen HJ, Huang N, Chen LS, Chou YJ, Li CP, Wu CY, Chang YC. Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan? PLoS One 2016;11:e0161002. [PMID: 27517172 DOI: 10.1371/journal.pone.0161002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
263 Lacaze L, Scotté M. Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma. World J Hepatol 2015;7:1755-60. [PMID: 26167248 DOI: 10.4254/wjh.v7.i13.1755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
264 Rombouts K, Carloni V. The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis Tissue Repair 2013;6:17. [PMID: 24350713 DOI: 10.1186/1755-1536-6-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
265 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
266 Kabbage L, El Kouhen M, Taghy A, Znati K, Kabbaj N. A rare presentation of hepatocellular carcinoma in non-cirrhotic liver. Pan Afr Med J 2017;28:69. [PMID: 29255539 DOI: 10.11604/pamj.2017.28.69.13512] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
267 Scaffaro LA, Kruel CD, Stella SF, Gravina GL, Machado Filho G, Borges de Almeida CP, Pinto LC, Alvares-da-Silva MR, Kruel CR. Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. Biomed Res Int 2015;2015:435120. [PMID: 26413523 DOI: 10.1155/2015/435120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
268 Li F, Dong X, Lin P, Jiang J. Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells. Int J Mol Sci 2018;19:E327. [PMID: 29360760 DOI: 10.3390/ijms19020327] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
269 Hasegawa K, Takata R, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. Int J Mol Sci. 2016;17. [PMID: 27626413 DOI: 10.3390/ijms17091500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
270 Wong KM, Yeh ML, Chuang SC, Wang LY, Lin ZY, Chen SC, Tsai JF, Wang SN, Kuo KK, Dai CY, Yu ML, Lee KT, Chuang WL. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol 2013;32:253-7. [PMID: 22932964 DOI: 10.1007/s12664-012-0225-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
271 Zhang X, Cheng SL, Bian K, Wang L, Zhang X, Yan B, Jia LT, Zhao J, Gammoh N, Yang AG, Zhang R. MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. Oncotarget 2015;6:2277-89. [PMID: 25537511 DOI: 10.18632/oncotarget.2956] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
272 Wang X, Liu S, Cao L, Zhang T, Yue D, Wang L, Ping Y, He Q, Zhang C, Wang M, Chen X, Gao Q, Wang D, Zhang Z, Wang F, Yang L, Li J, Huang L, Zhang B, Zhang Y. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget 2017;8:86592-603. [PMID: 29156819 DOI: 10.18632/oncotarget.21246] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
273 Jiang K, Li W, Zhang Q, Yan G, Guo K, Zhang S, Liu Y. GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness. Oncotarget. 2016;7:23530-23541. [PMID: 26993603 DOI: 10.18632/oncotarget.8120] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
274 Sarkar D, Fisher PB. AEG-1/MTDH/LYRIC: clinical significance. Adv Cancer Res 2013;120:39-74. [PMID: 23889987 DOI: 10.1016/B978-0-12-401676-7.00002-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
275 Ludwig DR, Fraum TJ, Cannella R, Ballard DH, Tsai R, Naeem M, LeBlanc M, Salter A, Tsung A, Shetty AS, Borhani AA, Furlan A, Fowler KJ. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdom Radiol (NY) 2019;44:2116-32. [PMID: 30798397 DOI: 10.1007/s00261-019-01948-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
276 Ozturk M, Batur T, Ekin U, Erdogan A, İscan E, Keles U, Oz O, Ozen C. Molecular Pathogenesis of Liver Cancer. J Gastrointest Cancer 2017;48:222-4. [PMID: 28718003 DOI: 10.1007/s12029-017-9957-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
277 Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L, Shen LM. Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. Cancer Cell Int. 2014;14:49. [PMID: 24991192 DOI: 10.1186/1475-2867-14-49] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 9.4] [Reference Citation Analysis]
278 Lin XM, Hu L, Gu J, Wang RY, Li L, Tang J, Zhang BH, Yan XZ, Zhu YJ, Hu CL, Zhou WP, Li S, Liu JF, Gonzalez FJ, Wu MC, Wang HY, Chen L. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression. Gastroenterology 2017;152:1187-202. [PMID: 28065789 DOI: 10.1053/j.gastro.2016.12.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
279 He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, Koike K, Karin M. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384-396. [PMID: 24120137 DOI: 10.1016/j.cell.2013.09.031] [Cited by in Crossref: 289] [Cited by in F6Publishing: 259] [Article Influence: 36.1] [Reference Citation Analysis]
280 Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol. 2014;20:786-794. [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
281 Güney İB. HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT). J Gastrointest Cancer 2017;48:276-80. [PMID: 28634672 DOI: 10.1007/s12029-017-9973-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
282 Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore). 2015;94:e639. [PMID: 25789957 DOI: 10.1097/md.0000000000000639] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
283 Wang J, McGrail DJ, Bhupal PK, Zhang W, Lin KY, Ku YH, Lin T, Wu H, Tsai KC, Li K, Peng CY, Finegold MJ, Lin SY, Tsai RYL. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. Mol Cancer Res 2020;18:723-34. [PMID: 32051231 DOI: 10.1158/1541-7786.MCR-19-0777] [Reference Citation Analysis]
284 Soliman AF, Abouelkhair MM, Hasab Allah MS, El-Kady NM, Ezzat WM, Gabr HA, Elsayed EH, Saleh AI, Kamel A. Efficacy and Safety of Microwave Ablation (MWA) for Hepatocellular Carcinoma (HCC) in Difficult Anatomical Sites in Egyptian Patients with Liver Cirrhosis. Asian Pac J Cancer Prev 2019;20:295-301. [PMID: 30678453 DOI: 10.31557/APJCP.2019.20.1.295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
285 Lee DH, Lee JM, Chang W, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK. Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. Eur Radiol 2018;28:3513-21. [PMID: 29488082 DOI: 10.1007/s00330-017-5278-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
286 Lu D, Han C, Wu T. 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Oncogene 2014;33:1101-12. [PMID: 23542179 DOI: 10.1038/onc.2013.69] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
287 Augustyn A, Peng L, Singal AG, Yopp AC. Surveillance for hepatocellular carcinoma secondary to cardiogenic cirrhosis in patients with congenital heart disease. Clin Res Cardiol 2015;104:446-9. [PMID: 25875944 DOI: 10.1007/s00392-015-0809-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
288 Feng H, Kuai JH, Zhang MY, Wang GC, Shi YJ, Zhang JY. Tumor necrosis factor-alpha gene -308G > A polymorphism alters the risk of hepatocellular carcinoma in a Han Chinese population. Diagn Pathol 2014;9:199. [PMID: 25420786 DOI: 10.1186/s13000-014-0199-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
289 Chen R, Xie Y, Zhong X, Fu Y, Huang Y, Zhen Y, Pan P, Wang H, Bartlett DL, Billiar TR, Lotze MT, Zeh HJ 3rd, Fan XG, Tang D, Kang R. Novel chemokine-like activities of histones in tumor metastasis. Oncotarget 2016;7:61728-40. [PMID: 27623211 DOI: 10.18632/oncotarget.11226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
290 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
291 Chidi AP, Bryce CL, Myaskovsky L, Fine MJ, Geller DA, Landsittel DP, Tsung A. Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma: A Retrospective Cohort Study. Ann Surg 2016;263:362-8. [PMID: 25563883 DOI: 10.1097/SLA.0000000000001111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
292 Wang F, Xie C, Zhao W, Deng Z, Yang H, Fang Q. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Clin Exp Med. 2017;17:33-43. [PMID: 26433964 DOI: 10.1007/s10238-015-0395-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
293 Morishita A, Iwama H, Fujihara S, Watanabe M, Fujita K, Tadokoro T, Ohura K, Chiyo T, Sakamoto T, Mimura S, Nomura T, Tani J, Yoneyama H, Okano K, Suzuki Y, Himoto T, Masaki T. Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing. Oncol Lett 2018;15:528-32. [PMID: 29391887 DOI: 10.3892/ol.2017.7334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
294 Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T. Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepat Med 2016;8:9-20. [PMID: 26955295 DOI: 10.2147/HMER.S63700] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
295 Kiyokawa H, Yasuda H, Oikawa R, Okuse C, Matsumoto N, Ikeda H, Watanabe T, Yamamoto H, Itoh F, Otsubo T, Yoshimura T, Yoshida E, Nakagawa M, Koshikawa N, Seiki M. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma. Cancer Sci 2017;108:1432-9. [PMID: 28418226 DOI: 10.1111/cas.13261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
296 Huang Y, Zhou S, Zhu J, Lubman DM, Mechref Y. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients. Electrophoresis 2017;38:2160-7. [PMID: 28543513 DOI: 10.1002/elps.201700025] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
297 Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB, Liang L, Jiang XM, Zhang QB, Tang ZY. Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. Evid Based Complement Alternat Med 2012;2012:908601. [PMID: 23326293 DOI: 10.1155/2012/908601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
298 Cui Y, Sun D, Song R, Zhang S, Liu X, Wang Y, Meng F, Lan Y, Han J, Pan S, Liang S, Zhang B, Guo H, Liu Y, Lu Z, Liu L. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis. J Cell Physiol 2019;234:22623-34. [PMID: 31106426 DOI: 10.1002/jcp.28828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
299 Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC. Modeling viral evolutionary dynamics after telaprevir-based treatment. PLoS Comput Biol 2014;10:e1003772. [PMID: 25101970 DOI: 10.1371/journal.pcbi.1003772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
300 Tsai TH, Song E, Zhu R, Di Poto C, Wang M, Luo Y, Varghese RS, Tadesse MG, Ziada DH, Desai CS. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics. 2015;15:2369-2381. [PMID: 25778709 DOI: 10.1002/pmic.201400364] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
301 Cheng S, Li T, Wang C, Wang K, Lai C, Yan J, Fan H, Sun F, Wang Z, Zhang P, Yu L, Hong Z, Lei G, Sun B, Gao Y, Xiao Z, Ji X, Wang R, Wu J, Wang X, Zhang S, Yang P. Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma. Oncotarget. 2018;9:36057-36066. [PMID: 30546827 DOI: 10.18632/oncotarget.23282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
302 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
303 Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, Li Y. The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development. Cell Death Differ 2020;27:420-33. [PMID: 31186535 DOI: 10.1038/s41418-019-0363-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
304 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
305 Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol 2016;22:458-65. [PMID: 28081589 DOI: 10.3350/cmh.2016.0054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
306 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
307 Wu R, Geng D, Chi X, Wang X, Gao X, Xu H, Shi Y, Guan Y, Wang Y, Jin J, Ding Y, Niu J. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019;12:2987-3015. [PMID: 31571951 DOI: 10.2147/idr.s218584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
308 Kirstein MM, Voigtländer T, Schweitzer N, Hinrichs JB, Marquardt J, Wörns MA, Kloeckner R, Fründt TW, Ittrich H, Wacker F, Rodt T, Manns MP, Wege H, Weinmann A, Vogel A. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterol J 2018;6:238-46. [PMID: 29511553 DOI: 10.1177/2050640617716597] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
309 Hu C, Zhao L, Li L. Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases. J Mol Med (Berl) 2021;99:179-92. [PMID: 33388882 DOI: 10.1007/s00109-020-02031-5] [Reference Citation Analysis]
310 Hu B, Sun M, Liu J, Hong G, Lin Q. MicroRNA-204 suppressed proliferation and motility capacity of human hepatocellular carcinoma via directly targeting zinc finger E-box binding homeobox 2. Oncol Lett 2017;13:3823-30. [PMID: 28521482 DOI: 10.3892/ol.2017.5907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
311 Li QM, Zhang FQ, Li YF, Xian QJ, Zhang YQ, Li P. Influence of polymorphisms in the Wnt/β-catenin pathway genes on hepatocellular carcinoma risk in a Chinese Han population. Medicine (Baltimore) 2017;96:e6127. [PMID: 28328801 DOI: 10.1097/MD.0000000000006127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
312 Jeong A, Kim JH, Lee HJ, Kim SH. Reactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells. Oncotarget 2017;8:70116-29. [PMID: 29050265 DOI: 10.18632/oncotarget.19592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
313 Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, Nistor GI, Cao W, Chen C, Dillman RO. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015;111:862-7. [PMID: 25873455 DOI: 10.1002/jso.23897] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
314 Zhu H, Han C, Wu T. MiR-17-92 cluster promotes hepatocarcinogenesis. Carcinogenesis. 2015;36:1213-1222. [PMID: 26233958 DOI: 10.1093/carcin/bgv112] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
315 Wang F, Li L, Piontek K, Sakaguchi M, Selaru FM. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology. 2018;67:940-954. [PMID: 29023935 DOI: 10.1002/hep.29586] [Cited by in Crossref: 94] [Cited by in F6Publishing: 99] [Article Influence: 31.3] [Reference Citation Analysis]
316 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
317 Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, López López C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer 2020;9:93-104. [PMID: 32071913 DOI: 10.1159/000504624] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
318 Pandit H, Li Y, Zheng Q, Guo W, Yu Y, Li S, Martin RCG. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget 2020;11:2047-60. [PMID: 32547703 DOI: 10.18632/oncotarget.27454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
319 Zhang ZM, Tan JX, Wang F, Dao FY, Zhang ZY, Lin H. Early Diagnosis of Hepatocellular Carcinoma Using Machine Learning Method. Front Bioeng Biotechnol 2020;8:254. [PMID: 32292778 DOI: 10.3389/fbioe.2020.00254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
320 Xiong F, Zhang F, Jin Y, Weng Q, Song J, Zhou G, Shin D, Zheng C, Yang X. Orthotopic hepatic cancer: radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy. Oncotarget 2018;9:14099-108. [PMID: 29581830 DOI: 10.18632/oncotarget.23586] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
321 Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol. 2020;26:6770-6781. [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
322 Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012;104:1599-1611. [PMID: 23073549 DOI: 10.1093/jnci/djs372] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
323 Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL; CiRCE Study Group. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Oncotarget 2017;8:62842-57. [PMID: 28968953 DOI: 10.18632/oncotarget.11327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
324 Dong S, Kong J, Kong F, Kong J, Gao J, Ke S, Wang S, Ding X, Sun W, Zheng L. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med 2013;11:273. [PMID: 24168056 DOI: 10.1186/1479-5876-11-273] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
325 Poursaid A, Price R, Tiede A, Olson E, Huo E, McGill L, Ghandehari H, Cappello J. In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization. Biomaterials 2015;57:142-52. [PMID: 25916502 DOI: 10.1016/j.biomaterials.2015.04.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
326 Ding J, Wen W, Xiang D, Yin P, Liu Y, Liu C, He G, Cheng Z, Yin J, Sheng C, Zhang W, Nan F, Ye W, Zhang X, Wang H. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. Oncotarget 2015;6:11627-39. [PMID: 25890498 DOI: 10.18632/oncotarget.3435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
327 White JA, Gray SH, Li P, Simpson HN, McGuire BM, Eckhoff DE, Abdel Aal AMK, Saddekni S, Dubay DA. Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement? Hepatol Commun 2017;1:338-46. [PMID: 29404463 DOI: 10.1002/hep4.1046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
328 Liao L, Duan D, Liu Y, Chen L. LHPP inhibits hepatocellular carcinoma cell growth and metastasis. Cell Cycle 2020;19:1846-54. [PMID: 32578511 DOI: 10.1080/15384101.2020.1783472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
329 Gao W, Li L, Han X, Liu S, Li C, Yu G, Zhang L, Zhang D, Liu C, Meng E, Hong S, Wang D, Guo P, Shi G. Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer 2021;21:331. [PMID: 33789609 DOI: 10.1186/s12885-021-08052-8] [Reference Citation Analysis]
330 Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Ruzzenente A, Pawlik TM. Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. World J Surg 2018;42:2551-60. [PMID: 29299649 DOI: 10.1007/s00268-017-4453-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
331 Shen J, Yeh CC, Wang Q, Gurvich I, Siegel AB, Santella RM. Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation. Anticancer Res 2016;36:5307-14. [PMID: 27798893 DOI: 10.21873/anticanres.11103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
332 Li TE, Zhang Z, Wang Y, Xu D, Dong J, Zhu Y, Wang Z. A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:2866-76. [PMID: 33854587 DOI: 10.7150/jca.54408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
334 Sun JY, Zhang XY, Cao YZ, Zhou X, Gu J, Mu XX. Diagnostic and prognostic value of circular RNAs in hepatocellular carcinoma. J Cell Mol Med 2020;24:5438-45. [PMID: 32281724 DOI: 10.1111/jcmm.15258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
335 Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen MS Jr. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. World J Gastroenterol 2016;22:8584-95. [PMID: 27784971 DOI: 10.3748/wjg.v22.i38.8584] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
336 Li SY, Huang PT, Fang Y, Wu Y, Zhou L, Luo JL, Wang XC, Chen YC. Ultrasonic Cavitation Ameliorates Antitumor Efficacy of Residual Cancer After Incomplete Radiofrequency Ablation in Rabbit VX2 Liver Tumor Model. Transl Oncol 2019;12:1113-21. [PMID: 31176089 DOI: 10.1016/j.tranon.2019.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
337 Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, Zhang XF, Zhang HX, Zhou ZQ, Zeng YX, Xia JC. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016;5:e1176653. [PMID: 27622026 DOI: 10.1080/2162402x.2016.1176653] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
338 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 175] [Article Influence: 36.6] [Reference Citation Analysis]
339 Xu WH, Zhang JB, Dang Z, Li X, Zhou T, Liu J, Wang DS, Song WJ, Dou KF. Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Int J Biol Sci. 2014;10:664-676. [PMID: 25013376 DOI: 10.7150/ijbs.8232] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
340 Desideri E, Ciriolo MR. Inhibition of JNK increases the sensitivity of hepatocellular carcinoma cells to lysosomotropic drugs via LAMP2A destabilization. Cell Death Discov 2021;7:29. [PMID: 33558496 DOI: 10.1038/s41420-021-00408-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Liu W, Zhou J, Sun Y, Zhang L, Xing B. Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. J Gastrointest Surg 2015;19:1271-80. [DOI: 10.1007/s11605-015-2811-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
342 Bertani S, Pineau P, Loli S, Moura J, Zimic M, Deharo E, Ruiz E. An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations. PLoS One 2013;8:e67756. [PMID: 23840771 DOI: 10.1371/journal.pone.0067756] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
343 Liu Z, Liao L, Cao Z, Chen X, Du J. Synergisic effect of APRIL knockdown and Jiedu Xiaozheng Yin, a Chinese medicinal recipe, on the inhibition of hepatocellular carcinoma cell proliferation. Oncol Rep 2017;37:754-60. [PMID: 28035399 DOI: 10.3892/or.2016.5339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
344 Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018;13:e0207132. [PMID: 30408106 DOI: 10.1371/journal.pone.0207132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
345 Ganesan M, Mathews S, Makarov E, Petrosyan A, Kharbanda KK, Kidambi S, Poluektova LY, Casey CA, Osna NA. Acetaldehyde suppresses HBV-MHC class I complex presentation on hepatocytes via induction of ER stress and Golgi fragmentation. Am J Physiol Gastrointest Liver Physiol 2020;319:G432-42. [PMID: 32755306 DOI: 10.1152/ajpgi.00109.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
346 Xu M, Fang S, Song J, Chen M, Zhang Q, Weng Q, Fan X, Chen W, Wu X, Wu F, Tu J, Zhao Z, Ji J. CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance. Cell Death Dis 2018;9:957. [PMID: 30237545 DOI: 10.1038/s41419-018-0974-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
347 Feng YH, Tung CL, Su YC, Tsao CJ, Wu TF. Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. Cancer Genomics Proteomics 2019;16:569-76. [PMID: 31659110 DOI: 10.21873/cgp.20159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
348 Ye Y, Long X, Zhang L, Chen J, Liu P, Li H, Wei F, Yu W, Ren X, Yu J. NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. Oncotarget 2016;7:70303-22. [PMID: 27611941 DOI: 10.18632/oncotarget.11854] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
349 Zhang R, Wang C, Tian Y, Yao Y, Mao J, Wang H, Li Z, Xu Y, Ye M, Wang L. SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis. J Cancer 2019;10:3871-82. [PMID: 31333804 DOI: 10.7150/jca.31266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
350 Hemmingsson J, Högberg J, Mölne J, Svensson J, Gjertsson P, Rizell M, Henrikson O, Bernhardt P. Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90 yttrium radioembolization demonstrate large absorbed dose heterogeneities. Adv Radiat Oncol 2018;3:439-46. [PMID: 30202811 DOI: 10.1016/j.adro.2018.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
351 Bisteau X, Caldez MJ, Kaldis P. The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) 2014;6:79-111. [PMID: 24419005 DOI: 10.3390/cancers6010079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
352 Li Y, Zhang Y, Zhang S, Huang D, Li B, Liang G, Wu Y, Jiang Q, Li L, Lin C, Wei Z, Meng L. circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis. Mol Ther Nucleic Acids 2021;23:244-54. [PMID: 33425483 DOI: 10.1016/j.omtn.2020.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
353 Chen YL, Lin PY, Ming YZ, Huang WC, Chen RF, Chen PM, Chu PY. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients. BMC Cancer 2017;17:474. [PMID: 28687090 DOI: 10.1186/s12885-017-3460-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
354 Liu G, Huang X, Cui X, Zhang J, Wei L, Ni R, Lu C. High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol 2013;30:537. [PMID: 23696020 DOI: 10.1007/s12032-013-0537-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
355 Chen W, Wang Y, Liang Q, Cai Y, Chen X, Zhang Y, Chen R, Xiao Y, Chen L. Efficacy and Safety of Aidi Injection Combined with Transcatheter Arterial Chemoembolization on Primary Hepatic Carcinoma: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2018;2018:6376429. [PMID: 30140297 DOI: 10.1155/2018/6376429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
356 Chiang CH, Kuo CS, Lin WW, Su JH, Chen JD, Huang KC. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study. Int J Environ Res Public Health 2019;16:E2097. [PMID: 31200528 DOI: 10.3390/ijerph16122097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:572-578. [PMID: 23333661 DOI: 10.1016/j.cgh.2012.12.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
358 Yoo JJ, Chung GE, Lee JH, Nam JY, Chang Y, Lee JM, Lee DH, Kim HY, Cho EJ, Yu SJ, Kim YJ, Yoon JH; Seoul Liver Group. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Res Treat 2018;50:366-73. [PMID: 28521494 DOI: 10.4143/crt.2017.126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
359 Li HY, Wei YG, Yan LN, Li B. Outcomes Between Elderly and Young Hepatocellular Carcinoma Living Donor Liver Transplantation Recipients: A Single-Center Experience. Medicine (Baltimore) 2016;95:e2499. [PMID: 26844458 DOI: 10.1097/MD.0000000000002499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
360 Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget 2016;7:16248-61. [PMID: 26919247 DOI: 10.18632/oncotarget.7637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
361 Liu Y, Wu H, Mei Y, Ding X, Yang X, Li C, Deng M, Gong J. Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma. Sci Rep 2017;7:15294. [PMID: 29127353 DOI: 10.1038/s41598-017-14813-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
362 Zhang B, Shi D, Zhang X, Liang G, Liu W, Qiao S. FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells. Oncol Lett. 2018;16:7231-7238. [PMID: 30546461 DOI: 10.3892/ol.2018.9541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
363 He L, Cai X, Cheng S, Zhou H, Zhang Z, Ren J, Ren F, Yang Q, Tao N, Chen J. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2019;17:5030-8. [PMID: 31186714 DOI: 10.3892/ol.2019.10174] [Reference Citation Analysis]
364 Wang ZX, Li L, Tao FY. Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy. J Pain Res 2018;11:2115-21. [PMID: 30319286 DOI: 10.2147/JPR.S166333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
365 Lu WJ, Chua MS, So SK. Suppressing N-Myc downstream regulated gene 1 reactivates senescence signaling and inhibits tumor growth in hepatocellular carcinoma. Carcinogenesis 2014;35:915-22. [PMID: 24302615 DOI: 10.1093/carcin/bgt401] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
366 Schütte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, Bretschneider T, Arend J, Ricke J, Malfertheiner P. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol. 2014;14:117. [PMID: 24990270 DOI: 10.1186/1471-230x-14-117] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
367 Zheng H, Chen T, Li C, Xu C, Ding C, Chen J, Ju S, Zhang Z, Liang Z, Cui Z, Zhao J. A circular RNA hsa_circ_0079929 inhibits tumor growth in hepatocellular carcinoma. Cancer Manag Res 2019;11:443-54. [PMID: 30655696 DOI: 10.2147/CMAR.S189338] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
368 Shiraishi Y, Fujimoto A, Furuta M, Tanaka H, Chiba K, Boroevich KA, Abe T, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Shibuya T, Nakano K, Sasaki A, Maejima K, Kitada R, Hayami S, Shigekawa Y, Marubashi S, Yamada T, Kubo M, Ishikawa O, Aikata H, Arihiro K, Ohdan H, Yamamoto M, Yamaue H, Chayama K, Tsunoda T, Miyano S, Nakagawa H. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. PLoS One 2014;9:e114263. [PMID: 25526364 DOI: 10.1371/journal.pone.0114263] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
369 Zhang T, Liu Y, Peng X, Fan J, Peng Z. Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation. Dis Markers 2017;2017:1754696. [PMID: 29162948 DOI: 10.1155/2017/1754696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
370 Li MM, Tang YQ, Gong YF, Cheng W, Li HL, Kong FE, Zhu WJ, Liu SS, Huang L, Guan XY, Ma NF, Liu M. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma. BMC Cancer 2019;19:851. [PMID: 31462277 DOI: 10.1186/s12885-019-6041-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
371 Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology. 2017;153:910-923. [PMID: 28807841 DOI: 10.1053/j.gastro.2017.08.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 24.8] [Reference Citation Analysis]
372 Korean Society of Abdominal Radiology. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-43. [PMID: 28458595 DOI: 10.3348/kjr.2017.18.3.427] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
373 Wen DY, Huang JC, Wang JY, Pan WY, Zeng JH, Pang YY, Yang H. Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: A comprehensive study using microarray and RNA sequencing data. Oncol Lett 2018;16:6918-29. [PMID: 30546424 DOI: 10.3892/ol.2018.9523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
374 Gu Q, Zhang B, Sun H, Xu Q, Tan Y, Wang G, Luo Q, Xu W, Yang S, Li J, Fu J, Chen L, Yuan S, Liang G, Ji Q, Chen SH, Chan CC, Zhou W, Xu X, Wang H, Fang DD. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget 2015;6:20160-76. [PMID: 26062443 DOI: 10.18632/oncotarget.3969] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
375 Tayob N, Lok AS, Do KA, Feng Z. Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol 2016;14:469-475.e2. [PMID: 26260109 DOI: 10.1016/j.cgh.2015.07.049] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
376 Wang Y, Wang G, Tan X, Ke K, Zhao B, Cheng N, Dang Y, Liao N, Wang F, Zheng X, Li Q, Liu X, Liu J. MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53. Oncogenesis 2019;8:67. [PMID: 31732712 DOI: 10.1038/s41389-019-0176-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
377 Chen H, Hu L, Luo Z, Zhang J, Zhang C, Qiu B, Dong L, Tan Y, Ding J, Tang S, Shen F, Li Z, Wang H. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression. Mol Cancer 2015;14:186. [PMID: 26538215 DOI: 10.1186/s12943-015-0454-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
378 Arora SP, Liposits G, Caird S, Dunne RF, Moffat GT, Okonji D, Rodriquenz MG, Dua D, Dotan E. Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. J Geriatr Oncol 2020;11:557-65. [PMID: 31704038 DOI: 10.1016/j.jgo.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
379 Xie ZB, Ma L, Wang XB, Bai T, Ye JZ, Zhong JH, Li LQ. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol. 2014;35:8451-8459. [PMID: 25038916 DOI: 10.1007/s13277-014-2340-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
380 Liu L, Zhang C, Zhao Y, Qi X, Chen H, Bai W, He C, Guo W, Yin Z, Fan D, Han G. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int. 2014;2014:194278. [PMID: 24800212 DOI: 10.1155/2014/194278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
381 Alonso S, Guerra AR, Carreira L, Ferrer JÁ, Gutiérrez ML, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol 2017;17:168. [PMID: 29268704 DOI: 10.1186/s12876-017-0726-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
382 VoPham T, Bertrand KA, Tamimi RM, Laden F, Hart JE. Ambient PM2.5 air pollution exposure and hepatocellular carcinoma incidence in the United States. Cancer Causes Control 2018;29:563-72. [PMID: 29696510 DOI: 10.1007/s10552-018-1036-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
383 Cabrera R, Fitian AI, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Liu C, Nelson DR. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncol Lett. 2012;4:840-846. [PMID: 23205111 DOI: 10.3892/ol.2012.826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
384 Molla MD, Dessie G, Akalu Y, Ayelign B. Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective. Int J Hepatol 2020;2020:2374615. [PMID: 32607257 DOI: 10.1155/2020/2374615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Singh A, Koduru B, Carlisle C, Akhter H, Liu RM, Schroder K, Brandes RP, Ojcius DM. NADPH oxidase 4 modulates hepatic responses to lipopolysaccharide mediated by Toll-like receptor-4. Sci Rep 2017;7:14346. [PMID: 29085012 DOI: 10.1038/s41598-017-14574-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
386 Li XL, Liu L, Li DD, He YP, Guo LH, Sun LP, Liu LN, Xu HX, Zhang XP. Integrin β4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Sci Rep 2017;7:40464. [PMID: 28084395 DOI: 10.1038/srep40464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
387 Xu M, Doyle MM, Banan B, Vachharajani N, Wang X, Saad N, Fowler K, Brunt EM, Lin Y, Chapman WC. Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Am Coll Surg. 2017;225:28-40. [PMID: 28400300 DOI: 10.1016/j.jamcollsurg.2017.03.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
388 Lu WJ, Saxena N, Luk JM, Kaul SC, Wadhwa R. Circulating mortalin autoantibody--a new serological marker of liver cirrhosis. Cell Stress Chaperones 2015;20:715-9. [PMID: 25905813 DOI: 10.1007/s12192-015-0592-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
389 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
390 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013;4:473-80. [PMID: 23901347 DOI: 10.7150/jca.6609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
391 Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol. 2015;21:4103-4110. [PMID: 25892859 DOI: 10.3748/wjg.v21.i14.4103] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 69] [Article Influence: 16.6] [Reference Citation Analysis]
392 Zhang S, Li L, Kendrick SL, Gerard RD, Zhu H. TALEN-mediated somatic mutagenesis in murine models of cancer. Cancer Res. 2014;74:5311-5321. [PMID: 25070752 DOI: 10.1158/0008-5472.can-14-0529] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
393 Tsirulnikov K, Duarte S, Ray A, Datta N, Zarrinpar A, Hwang L, Faull K, Pushkin A, Kurtz I. Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma. J Cancer 2018;9:1-12. [PMID: 29290764 DOI: 10.7150/jca.21747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
394 Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology 2013;2:e26468. [PMID: 24498546 DOI: 10.4161/onci.26468] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
395 Kasinski AL, Slack FJ. Arresting the Culprit: Targeted Antagomir Delivery to Sequester Oncogenic miR-221 in HCC. Mol Ther Nucleic Acids 2012;1:e12. [PMID: 23343881 DOI: 10.1038/mtna.2012.2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
396 Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They? Cell Metab 2019;29:18-26. [PMID: 30449681 DOI: 10.1016/j.cmet.2018.10.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 19.0] [Reference Citation Analysis]
397 Yin Z, Jiang K, Li R, Dong C, Wang L. Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy. Mol Cancer. 2018;17:178. [PMID: 30593276 DOI: 10.1186/s12943-018-0926-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
398 Yin S, Fan Y, Zhang H, Zhao Z, Hao Y, Li J, Sun C, Yang J, Yang Z, Yang X, Lu J, Xi JJ. Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. Nat Commun 2016;7:11012. [PMID: 26987776 DOI: 10.1038/ncomms11012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
399 Paganoni R, Lechel A, Vujic Spasic M. Iron at the Interface of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4097. [PMID: 33921027 DOI: 10.3390/ijms22084097] [Reference Citation Analysis]
400 Gandhy SU, Imanirad P, Jin UH, Nair V, Hedrick E, Cheng Y, Corton JC, Kim K, Safe S. Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC. Oncotarget 2015;6:26359-72. [PMID: 26317792 DOI: 10.18632/oncotarget.4560] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
401 Rowe IA, Galsinh SK, Wilson GK, Parker R, Durant S, Lazar C, Branza-Nichita N, Bicknell R, Adams DH, Balfe P. Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology. 2014;59:375-384. [PMID: 23775568 DOI: 10.1002/hep.26571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
402 Jariwala N, Mendoza RG, Garcia D, Lai Z, Subler MA, Windle JJ, Mukhopadhyay ND, Fisher PB, Chen Y, Sarkar D. Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma. Hepatol Commun 2019;3:1258-70. [PMID: 31497746 DOI: 10.1002/hep4.1400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
403 Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clin Cancer Res. 2014;20:1274-1287. [PMID: 24520095 DOI: 10.1158/1078-0432.ccr-12-3909] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
404 Shebl FM, Capo-Ramos DE, Graubard BI, McGlynn KA, Altekruse SF. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2012;21:1330-5. [PMID: 22669949 DOI: 10.1158/1055-9965.EPI-12-0124] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
405 Yan MD, Yao CJ, Chow JM, Chang CL, Hwang PA, Chuang SE, Whang-Peng J, Lai GM. Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma Cells. Mar Drugs 2015;13:6099-116. [PMID: 26404322 DOI: 10.3390/md13106099] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
406 Hong Y, Ye M, Wang F, Fang J, Wang C, Luo J, Liu J, Liu J, Liu L, Zhao Q, Chang Y. MiR-21-3p Promotes Hepatocellular Carcinoma Progression via SMAD7/YAP1 Regulation. Front Oncol 2021;11:642030. [PMID: 33763375 DOI: 10.3389/fonc.2021.642030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
407 Liang X, Wang Y, Shi H, Dong M, Han H, Li Q. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment. Int J Nanomedicine 2021;16:2569-84. [PMID: 33833512 DOI: 10.2147/IJN.S304526] [Reference Citation Analysis]
408 Wang G, Liu J, Cai Y, Chen J, Xie W, Kong X, Huang W, Guo H, Zhao X, Lu Y, Niu L, Li X, Zhang H, Lei C, Lei Z, Yin J, Hu H, Yu F, Nie Y, Xia L, Wu K. Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis. Oncotarget 2017;8:71867-80. [PMID: 29069753 DOI: 10.18632/oncotarget.18288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
409 Ram AK, Pottakat B, Vairappan B. Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma. BMC Cancer. 2018;18:572. [PMID: 29776350 DOI: 10.1186/s12885-018-4484-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
410 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
411 Brahma MK, Gilglioni EH, Zhou L, Trépo E, Chen P, Gurzov EN. Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. Oncogene 2021. [PMID: 34290399 DOI: 10.1038/s41388-021-01950-y] [Reference Citation Analysis]
412 Zhang X, Lin X, Qiu H, Peng Z. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres® Microspheres in treating Chinese hepatocellular carcinoma patients. J Clin Lab Anal 2019;33:e22975. [PMID: 31328832 DOI: 10.1002/jcla.22975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
413 Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573-581. [PMID: 23846171 DOI: 10.1038/bjc.2013.352] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
414 Liu XY, Xu JF. Liver resection for young patients with large hepatocellular carcinoma: a single center experience from China. World J Surg Oncol 2014;12:175. [PMID: 24894964 DOI: 10.1186/1477-7819-12-175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
415 Robertson CL, Srivastava J, Siddiq A, Gredler R, Emdad L, Rajasekaran D, Akiel M, Shen XN, Guo C, Giashuddin S. Genetic deletion of AEG-1 prevents hepatocarcinogenesis. Cancer Res. 2014;74:6184-6193. [PMID: 25193383 DOI: 10.1158/0008-5472.CAN-14-1357] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
416 Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, Santoro R, Lepiane P, Sciuto R, Pizzi G, Cianni R, Golfieri R, D'Offizi G, Pellicelli AM, Antonini M, Vennarecci G. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017;41:241-9. [PMID: 27495316 DOI: 10.1007/s00268-016-3682-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
417 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
418 Wu B, Jiang Y, Zhu F, Sun D, Huang H. Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703. Oncol Lett 2016;11:2545-51. [PMID: 27073515 DOI: 10.3892/ol.2016.4243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
419 Czauderna C, Palestino-Dominguez M, Castven D, Becker D, Zanon-Rodriguez L, Hajduk J, Mahn FL, Herr M, Strand D, Strand S, Heilmann-Heimbach S, Gomez-Quiroz LE, Wörns MA, Galle PR, Marquardt JU. Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver. PLoS One 2018;13:e0209067. [PMID: 30576355 DOI: 10.1371/journal.pone.0209067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
420 Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Dig Dis Sci. 2020;65:658-667. [PMID: 31659612 DOI: 10.1007/s10620-019-05813-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
421 Ge K, Huang J, Wang W, Gu M, Dai X, Xu Y, Wu H, Li G, Lu H, Zhong J, Huang Q. Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action. Oncotarget 2017;8:5965-75. [PMID: 27999203 DOI: 10.18632/oncotarget.13983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
422 Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Yang HD, Park M, Park WS, Kang YK, Nam SW. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget 2015;6:8089-102. [PMID: 25797269 DOI: 10.18632/oncotarget.3512] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 15.4] [Reference Citation Analysis]
423 Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: Surgeon’s view on latest findings and future perspectives. World J Hepatol. 2015;7:1168-1183. [PMID: 26019733 DOI: 10.4254/wjh.v7.i9.1168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
424 Zhang P, Liu Q, Yuan M, Wang L. Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis. Infect Agent Cancer 2018;13:30. [PMID: 30181772 DOI: 10.1186/s13027-018-0203-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
425 Zhu Q, Li N, Li F, Zhou Z, Sang J, Zeng X, Han Q, Lv Y, Zhao W, Liu Z. How admissions to various medical specialty divisions determines the outcome of patients with hepatocellular carcinoma: results from a retrospective study in a large hospital of northwest China. Ther Clin Risk Manag 2017;13:545-53. [PMID: 28458557 DOI: 10.2147/TCRM.S131290] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 185] [Cited by in F6Publishing: 161] [Article Influence: 23.1] [Reference Citation Analysis]
427 Velez E, Goldberg SN, Kumar G, Wang Y, Gourevitch S, Sosna J, Moon T, Brace CL, Ahmed M. Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor Growth. Radiology 2016;281:782-92. [PMID: 27409564 DOI: 10.1148/radiol.2016152241] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
428 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
429 Zhu SL, Zhong JH, Gong WF, Li H, Li LQ. Association of the miR-196a2 C>T and miR-499 A>G polymorphisms with hepatitis B virus-related hepatocellular carcinoma risk: an updated meta-analysis. Onco Targets Ther 2016;9:2111-9. [PMID: 27143913 DOI: 10.2147/OTT.S96738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
430 Murakami Y, Kubo S, Tamori A, Itami S, Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T, Taguchi YH. Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci Rep 2015;5:16294. [PMID: 26538415 DOI: 10.1038/srep16294] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
431 Dang H, Takai A, Forgues M, Pomyen Y, Mou H, Xue W, Ray D, Ha KCH, Morris QD, Hughes TR, Wang XW. Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. Cancer Cell 2017;32:101-114.e8. [PMID: 28697339 DOI: 10.1016/j.ccell.2017.06.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 17.3] [Reference Citation Analysis]
432 Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr) 2020;43:1203-14. [PMID: 32797385 DOI: 10.1007/s13402-020-00552-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
433 Tayob N, Stingo F, Do KA, Lok ASF, Feng Z. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics 2018;74:249-59. [PMID: 28482112 DOI: 10.1111/biom.12717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
434 Katz LH, Likhter M, Jogunoori W, Belkin M, Ohshiro K, Mishra L. TGF-β signaling in liver and gastrointestinal cancers. Cancer Lett 2016;379:166-72. [PMID: 27039259 DOI: 10.1016/j.canlet.2016.03.033] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 12.8] [Reference Citation Analysis]
435 Chen X, Liao Y, Yu Y, Zhu P, Li J, Qin L, Liao W, Huang Z. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget 2017;8:92589-603. [PMID: 29190940 DOI: 10.18632/oncotarget.21506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
436 Rajasekaran D, Srivastava J, Ebeid K, Gredler R, Akiel M, Jariwala N, Robertson CL, Shen XN, Siddiq A, Fisher PB, Salem AK, Sarkar D. Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC). Bioconjug Chem 2015;26:1651-61. [PMID: 26079152 DOI: 10.1021/acs.bioconjchem.5b00254] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
437 Matsuda M, Seki E. Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Semin Liver Dis 2020;40:307-20. [PMID: 32242330 DOI: 10.1055/s-0040-1708876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
438 Zhang Y, Ren JS, Shi JF, Li N, Wang YT, Qu C, Zhang Y, Dai M. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer. 2015;15:94. [PMID: 25879744 DOI: 10.1186/s12885-015-1113-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
439 Dong H, Zhang L, Qian Z, Zhu X, Zhu G, Chen Y, Xie X, Ye Q, Zang J, Ren Z, Ji Q. Identification of HBV-MLL4 Integration and Its Molecular Basis in Chinese Hepatocellular Carcinoma. PLoS One. 2015;10:e0123175. [PMID: 25901726 DOI: 10.1371/journal.pone.0123175] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
440 Ocsoy I, Gulbakan B, Shukoor MI, Xiong X, Chen T, Powell DH, Tan W. Aptamer-conjugated multifunctional nanoflowers as a platform for targeting, capture, and detection in laser desorption ionization mass spectrometry. ACS Nano 2013;7:417-27. [PMID: 23211039 DOI: 10.1021/nn304458m] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 8.3] [Reference Citation Analysis]
441 Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clin Cancer Res. 2017;23:7333-7339. [PMID: 28928158 DOI: 10.1158/1078-0432.ccr-17-0950] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 13.5] [Reference Citation Analysis]
442 Zhang Y, Brodin NP, Ohri N, Thibaud S, Kaubisch A, Kinkhabwala M, Garg M, Guha C, Kabarriti R. Association between neutrophil-lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma. Hepatol Int 2019;13:609-17. [PMID: 31372942 DOI: 10.1007/s12072-019-09965-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
443 Fujiwara N, Tateishi R, Akahane M, Taguri M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Ohtomo K, Koike K. Changes in risk of immediate adverse reactions to iodinated contrast media by repeated administrations in patients with hepatocellular carcinoma. PLoS One 2013;8:e76018. [PMID: 24098420 DOI: 10.1371/journal.pone.0076018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
444 Bharadwaj S, Gohel TD. Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2016;4:237-40. [PMID: 25563577 DOI: 10.1093/gastro/gou089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
445 Xing J, Spradling PR, Moorman AC, Holmberg SD, Teshale EH, Rupp LB, Gordon SC, Lu M, Boscarino JA, Schmidt MA, Trinacty CM, Xu F; Chronic Hepatitis Cohort Study (CHeCS) Investigators. A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C. Dig Dis Sci 2017;62:3221-34. [PMID: 28965221 DOI: 10.1007/s10620-017-4762-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
446 Sakamaki A, Kamimura K, Abe S, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S. Spontaneous regression of hepatocellular carcinoma: A mini-review. World J Gastroenterol 2017;23:3797-804. [PMID: 28638219 DOI: 10.3748/wjg.v23.i21.3797] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
447 Kai F, Laklai H, Weaver VM. Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease. Trends Cell Biol 2016;26:486-97. [PMID: 27056543 DOI: 10.1016/j.tcb.2016.03.007] [Cited by in Crossref: 131] [Cited by in F6Publishing: 106] [Article Influence: 26.2] [Reference Citation Analysis]
448 Shang R, Song X, Wang P, Zhou Y, Lu X, Wang J, Xu M, Chen X, Utpatel K, Che L, Liang B, Cigliano A, Evert M, Calvisi DF, Chen X. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut 2021;70:1746-57. [PMID: 33144318 DOI: 10.1136/gutjnl-2020-320716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
449 Kurahashi T, Yoshida Y, Ogura S, Egawa M, Furuta K, Hikita H, Kodama T, Sakamori R, Kiso S, Kamada Y, Wang IC, Eguchi H, Morii E, Doki Y, Mori M, Kalinichenko VV, Tatsumi T, Takehara T. Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. Cell Mol Gastroenterol Hepatol 2020;9:425-46. [PMID: 31669262 DOI: 10.1016/j.jcmgh.2019.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
450 Khambu B, Hong H, Liu S, Liu G, Chen X, Dong Z, Wan J, Yin XM. The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors. Cell Death Dis 2020;11:333. [PMID: 32382012 DOI: 10.1038/s41419-020-2536-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
451 Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, Kanwal F, El-Serag HB. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858-1868. [PMID: 23359313 DOI: 10.1002/hep.26287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
452 Saito R, Amemiya H, Hosomura N, Kawaida H, Maruyama S, Shimizu H, Furuya S, Akaike H, Kawaguchi Y, Sudo M, Inoue S, Kono H, Ichikawa D. Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection. In Vivo 2020;34:1265-70. [PMID: 32354917 DOI: 10.21873/invivo.11900] [Reference Citation Analysis]
453 Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT, Chan TA, Tsung A, Otsuji E, Takabe K. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1221. [PMID: 32414098 DOI: 10.3390/cancers12051221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
454 Repana D, Ross P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases 2015;3:294-305. [PMID: 28943626 DOI: 10.3390/diseases3040294] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
455 Liu Y, Wang X, Yang Y. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma. Clin Mol Hepatol 2020;26:742-50. [PMID: 32981290 DOI: 10.3350/cmh.2020.0178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
456 Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12:292-302. [PMID: 25308752 DOI: 10.1038/cmi.2014.91] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 12.1] [Reference Citation Analysis]
457 Defamie V, Sanchez O, Murthy A, Khokha R. TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene. 2015;34:4098-4108. [PMID: 25347747 DOI: 10.1038/onc.2014.339] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
458 Peng H, Zhang Y, Zhou Z, Guo Y, Huang X, Westover KD, Zhang Z, Chen B, Hua Y, Li S, Xu R, Lin N, Peng B, Shen S. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. EBioMedicine 2019;46:105-18. [PMID: 31324602 DOI: 10.1016/j.ebiom.2019.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
459 Fusco M, Piselli P, Virdone S, Di Cicco P, Scognamiglio P, De Paoli P, Ciullo V, Verdirosi D, D'Orazio M, Dal Maso L, Girardi E, Franceschi S, Serraino D. Infection with hepatitis viruses, FIB-4 index and risk of hepatocellular carcinoma in southern Italy: a population-based cohort study. Infect Agent Cancer. 2016;11:54. [PMID: 27822295 DOI: 10.1186/s13027-016-0101-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
460 Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-11. [PMID: 25822088 DOI: 10.1038/ng.3252] [Cited by in Crossref: 792] [Cited by in F6Publishing: 709] [Article Influence: 132.0] [Reference Citation Analysis]
461 Dong Y, Zou J, Su S, Huang H, Deng Y, Wang B, Li W. MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. Mol Med Rep 2015;12:1016-22. [PMID: 25816091 DOI: 10.3892/mmr.2015.3516] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
462 Song W, Zhang J, Xia Q, Sun M. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway. Cell Cycle 2019;18:3177-88. [PMID: 31564201 DOI: 10.1080/15384101.2019.1671089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
463 Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014;49:9-23. [PMID: 24318021 DOI: 10.1007/s00535-013-0907-x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 9.1] [Reference Citation Analysis]
464 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 6.8] [Reference Citation Analysis]
465 Wang J, Chen X, Zhou Z, Li J, Sun H. The Inhibitory Effect of 3 β -Hydroxy-12-oleanen-27-oic Acid on Growth and Motility of Human Hepatoma HepG2 Cells through JNK and Akt Signaling Pathway. Evid Based Complement Alternat Med 2013;2013:685159. [PMID: 24379889 DOI: 10.1155/2013/685159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
466 Bai F, Zhou H, Ma M, Guan C, Lyu J, Meng QH. A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of hepatocellular carcinoma. Mol Oncol 2018;12:1125-37. [PMID: 29719937 DOI: 10.1002/1878-0261.12315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
467 Webster NJG. Alternative RNA Splicing in the Pathogenesis of Liver Disease. Front Endocrinol (Lausanne) 2017;8:133. [PMID: 28680417 DOI: 10.3389/fendo.2017.00133] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
468 Yu K, Tang J, Wu JL, Li B, Wu SN, Zhang MY, Li QY, Zhang LJ, Pan YC, Ge QM, Shu HY, Shao Y. Risk factors for intraocular metastasis of primary liver cancer in diabetic patients: Alpha-fetoprotein and cancer antigen 125. World J Diabetes 2021;12:158-69. [PMID: 33594335 DOI: 10.4239/wjd.v12.i2.158] [Reference Citation Analysis]
469 Connell LC, Harding JJ, Abou-Alfa GK. Advanced Hepatocellular Cancer: the Current State of Future Research. Curr Treat Options Oncol. 2016;17:43. [PMID: 27344158 DOI: 10.1007/s11864-016-0415-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
470 Peveling-Oberhag J, Seiz A, Döring C, Hartmann S, Köberle V, Liese J, Zeuzem S, Hansmann ML, Piiper A. MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol 2014;7:672-80. [PMID: 25500075 DOI: 10.1016/j.tranon.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
471 Salvi A, Bongarzone I, Ferrari L, Abeni E, Arici B, De Bortoli M, Scuri S, Bonini D, Grossi I, Benetti A, Baiocchi G, Portolani N, De Petro G. Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells. Int J Oncol 2015;46:1901-12. [PMID: 25760690 DOI: 10.3892/ijo.2015.2923] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
472 Ilikhan SU, Bilici M, Sahin H, Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol 2015;21:6999-7007. [PMID: 26078578 DOI: 10.3748/wjg.v21.i22.6999] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
473 Sanoff HK, Chang Y, Reimers M, Lund JL. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma. J Oncol Pract 2017;13:e197-206. [PMID: 28029300 DOI: 10.1200/JOP.2016.017814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
474 Gao L, Zhang J, Ma T, Yao N, Gao M, Shan X, Ni Y, Shao H, Xu K. Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy. Oncotarget 2016;7:51450-61. [PMID: 27285983 DOI: 10.18632/oncotarget.9848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
475 Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med. 2018;7:4570-4583. [PMID: 30109780 DOI: 10.1002/cam4.1664] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
476 Zhao Y, Chen J, Wei W, Qi X, Li C, Ren J. The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduct Target Ther 2018;3:3. [PMID: 29527329 DOI: 10.1038/s41392-017-0003-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
477 Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014;74:487-95. [PMID: 25030088 DOI: 10.1007/s00280-014-2495-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
478 de Carvalho FM, de Almeida Pereira T, Gonçalves PL, Jarske RD, Pereira FE, Louro ID. Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Mol Biol Rep 2013;40:4883-7. [PMID: 23649769 DOI: 10.1007/s11033-013-2587-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
479 Giordano A, Tommonaro G. Curcumin and Cancer. Nutrients 2019;11:E2376. [PMID: 31590362 DOI: 10.3390/nu11102376] [Cited by in Crossref: 120] [Cited by in F6Publishing: 79] [Article Influence: 60.0] [Reference Citation Analysis]
480 Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, Xi SY, Zhao Y, Zhang Y, Yuan YF, Ma NF, Ma S, Guan XY, Liu M. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer 2021;20:20. [PMID: 33485358 DOI: 10.1186/s12943-021-01315-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
481 Kudo M. Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer 2012;1:141-3. [PMID: 24159578 DOI: 10.1159/000342749] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
482 Zhao X, Zhou S, Wang D, He W, Li J, Zhang S. MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A. Oncol Lett 2018;16:2207-14. [PMID: 30008920 DOI: 10.3892/ol.2018.8933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
483 Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y, Tian T. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017;108:620-631. [PMID: 28132399 DOI: 10.1111/cas.13177] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 16.0] [Reference Citation Analysis]
484 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
485 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021;13:795-824. [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
486 Lou G, Dong X, Xia C, Ye B, Yan Q, Wu S, Yu Y, Liu F, Zheng M, Chen Z, Liu Y. Direct targeting sperm-associated antigen 9 by miR-141 influences hepatocellular carcinoma cell growth and metastasis via JNK pathway. J Exp Clin Cancer Res 2016;35:14. [PMID: 26790956 DOI: 10.1186/s13046-016-0289-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
487 Cui X, Li Z, Gao J, Gao PJ, Ni YB, Zhu JY. Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. Oncotarget. 2016;7:65052-65066. [PMID: 27542259 DOI: 10.18632/oncotarget.11350] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
488 Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2013;2013:430438. [PMID: 23710167 DOI: 10.1155/2013/430438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
489 Ling C, Wang Y, Zhang Y, Ejjigani A, Yin Z, Lu Y, Wang L, Wang M, Li J, Hu Z, Aslanidi GV, Zhong L, Gao G, Srivastava A, Ling C. Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum Gene Ther 2014;25:1023-34. [PMID: 25296041 DOI: 10.1089/hum.2014.099] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
490 Zhou H, Du X, Zhang Z. Electrochemical Sensors for Detection of Markers on Tumor Cells. Int J Mol Sci 2021;22:8184. [PMID: 34360949 DOI: 10.3390/ijms22158184] [Reference Citation Analysis]
491 Zhang R, Guo H, Xu J, Li B, Liu YJ, Cheng C, Zhou C, Zhao Y, Liu Y. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget 2016;7:60609-22. [PMID: 27542264 DOI: 10.18632/oncotarget.11300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
492 Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer. 2012;1:201-215. [PMID: 24159585 DOI: 10.1159/000343835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
493 Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma. PLoS One 2012;7:e46318. [PMID: 23029478 DOI: 10.1371/journal.pone.0046318] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
494 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
495 Bai Y, Qi W, Liu L, Zhang J, Pang L, Gan T, Wang P, Wang C, Chen H. Identification of Seven-Gene Hypoxia Signature for Predicting Overall Survival of Hepatocellular Carcinoma. Front Genet 2021;12:637418. [PMID: 33912215 DOI: 10.3389/fgene.2021.637418] [Reference Citation Analysis]
496 Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016;7:75482-75491. [PMID: 27776351 DOI: 10.18632/oncotarget.12780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
497 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Reference Citation Analysis]
498 Xu Y, Chen T, Liao D, Wu X, Zhong Y, Liu S, Yang H, Nie Y. The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition. Tumour Biol 2016;37:11311-20. [PMID: 26951515 DOI: 10.1007/s13277-016-4998-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
499 Liu HT, Cheng SB, Huang YC, Huang YT, Lin PT. Coenzyme Q10 and Oxidative Stress: Inflammation Status in Hepatocellular Carcinoma Patients after Surgery. Nutrients 2017;9:E29. [PMID: 28054958 DOI: 10.3390/nu9010029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
500 De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, Brenner D, Alvaro D, Alpini G, Marzioni M. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis 2013;45:450-9. [PMID: 23177172 DOI: 10.1016/j.dld.2012.10.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
501 Zha R, Guo W, Zhang Z, Qiu Z, Wang Q, Ding J, Huang S, Chen T, Gu J, Yao M, He X. Genome-wide screening identified that miR-134 acts as a metastasis suppressor by targeting integrin β1 in hepatocellular carcinoma. PLoS One 2014;9:e87665. [PMID: 24498348 DOI: 10.1371/journal.pone.0087665] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
502 Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, Zhao W, Yi F, Tang W. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260. [PMID: 26879559 DOI: 10.1038/srep21260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
503 Xiang X, Deng L, Xiong R, Xiao D, Chen Z, Yang F, Liu K, Feng G. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma. Cell Cycle 2018;17:1310-8. [PMID: 30045663 DOI: 10.1080/15384101.2018.1480208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
504 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
505 Elnekave E, Erinjeri JP, Brown KT, Thornton RH, Petre EN, Maybody M, Maluccio MA, Hsu M, Sofocleous CT, Getrajdman GI. Long-term outcomes comparing surgery to embolization-ablation for treatment of solitary HCC& lt; 7 cm. Ann Surg Oncol. 2013;20:2881-2886. [PMID: 23563960 DOI: 10.1245/s10434-013-2961-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
506 Chuang MH, Chang JT, Hsu LJ, Jan MS, Lu FJ. Antitumor Activity of the Chinese Medicine JC-001 Is Mediated by Immunomodulation in a Murine Model of Hepatocellular Carcinoma. Integr Cancer Ther 2017;16:516-25. [PMID: 27698264 DOI: 10.1177/1534735416664173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
507 Munakarmi S, Chand L, Shin HB, Hussein UK, Yun BS, Park HR, Jeong YJ. Anticancer effects of Poncirus fructus on hepatocellular carcinoma through regulation of apoptosis, migration, and invasion. Oncol Rep 2020;44:2537-46. [PMID: 33125135 DOI: 10.3892/or.2020.7790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
508 Daugherity EK, Balmus G, Al Saei A, Moore ES, Abi Abdallah D, Rogers AB, Weiss RS, Maurer KJ. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle. 2012;11:1918-1928. [PMID: 22544329 DOI: 10.4161/cc.20259] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
509 David N, Yaffe Y, Hagoel L, Elazar M, Glenn JS, Hirschberg K, Sklan EH. The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication. Virology. 2015;475:139-149. [PMID: 25462354 DOI: 10.1016/j.virol.2014.10.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
510 Li J, Chen M, Wang ZJ, Li SG, Jiang M, Shi L, Cao CL, Sang T, Cui XW, Dietrich CF. Interobserver agreement for contrast-enhanced ultrasound of liver imaging reporting and data system: A systematic review and meta-analysis. World J Clin Cases 2020;8:5589-602. [PMID: 33344549 DOI: 10.12998/wjcc.v8.i22.5589] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
511 Lu DH, Lv WW, Li WX, Gao YD. High PKM2 expression is independently correlated with decreased overall survival in hepatocellular carcinoma. Oncol Lett 2018;16:3603-10. [PMID: 30127967 DOI: 10.3892/ol.2018.9100] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
512 Feng Y, Chen Y, Meng Y, Cao Q, Liu Q, Ling C, Wang C. Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy. Oncoimmunology 2018;7:e1426434. [PMID: 29721392 DOI: 10.1080/2162402X.2018.1426434] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
513 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54. [PMID: 25153274 DOI: 10.1148/radiol.14132361] [Cited by in Crossref: 236] [Cited by in F6Publishing: 194] [Article Influence: 33.7] [Reference Citation Analysis]
514 Bauer U, Mogler C, Braren RF, Algül H, Schmid RM, Ehmer U. Progression after Immunotherapy for Fibrolamellar Carcinoma. Visc Med 2019;35:39-42. [PMID: 31312648 DOI: 10.1159/000497464] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
515 Zou WY, El-Serag HB, Sada YH, Temple SL, Sansgiry S, Kanwal F, Davila JA. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci 2018;63:1173-81. [PMID: 29508165 DOI: 10.1007/s10620-018-4989-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
516 Ding Z, Ericksen RE, Lee QY, Han W. Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis. Amino Acids 2021. [PMID: 33646427 DOI: 10.1007/s00726-021-02961-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
517 Tang L, Zhu H, Yang X, Xie F, Peng J, Jiang D, Xie J, Qi M, Yu L. Shizukaol D, a Dimeric Sesquiterpene Isolated from Chloranthus serratus, Represses the Growth of Human Liver Cancer Cells by Modulating Wnt Signalling Pathway. PLoS One 2016;11:e0152012. [PMID: 27010735 DOI: 10.1371/journal.pone.0152012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
518 Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, Silini EM, Sabbioni S, Negrini M. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene 2019;38:7035-45. [PMID: 31409896 DOI: 10.1038/s41388-019-0942-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
519 Chen S, Li J, Tan X, Xu Q, Mo Y, Qin H, Zhou L, Ma L, Wei Z. Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma: Evidence from literature and an original study. J Clin Lab Anal 2020;34:e23262. [PMID: 32167614 DOI: 10.1002/jcla.23262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
520 Liu C, Li F, Li X, Cao M, Feng G, Yuan X, Shi X. WIPI2 depletion inhibits the growth of hepatocellular carcinoma cells through the AMPK signaling pathway. Oncol Rep 2020;43:1467-78. [PMID: 32323845 DOI: 10.3892/or.2020.7531] [Reference Citation Analysis]
521 Yang Z, Liu S, Zhu M, Zhang H, Wang J, Xu Q, Lin K, Zhou X, Tao M, Li C. PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway. Sci Rep. 2016;6:22090. [PMID: 26915315 DOI: 10.1038/srep22090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
522 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 132] [Article Influence: 20.7] [Reference Citation Analysis]
523 Drozdov I, Bornschein J, Wex T, Valeyev NV, Tsoka S, Malfertheiner P. Functional and topological properties in hepatocellular carcinoma transcriptome. PLoS One 2012;7:e35510. [PMID: 22539975 DOI: 10.1371/journal.pone.0035510] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
524 Kanogawa N, Chiba T, Ogasawara S, Ooka Y, Suzuki E, Motoyama T, Saito T, Sekimoto T, Tawada A, Maruyama H, Yoshikawa M, Yokosuka O. Successful interventional treatment for arterioportal fistula caused by radiofrequency ablation for hepatocellular carcinoma. Case Rep Oncol 2014;7:833-9. [PMID: 25685134 DOI: 10.1159/000370305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
525 Ma KW, Chan ACY, Chok KSH, She WH, Cheung TT, Dai WC, Fung JYY, Lo CM. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion? Hepatobiliary Surg Nutr 2021;10:308-14. [PMID: 34159158 DOI: 10.21037/hbsn.2020.03.09] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases. Meta Gene 2013;1:126-37. [PMID: 25606382 DOI: 10.1016/j.mgene.2013.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
527 Scherber PR, Gäbelein G, Eisele RM, Igna D, Glanemann M. [Early stage liver cancer : Hepatocellular carcinoma]. Chirurg 2018;89:281-8. [PMID: 29075797 DOI: 10.1007/s00104-017-0538-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
528 Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Des Devel Ther 2021;15:1873-82. [PMID: 33976538 DOI: 10.2147/DDDT.S304857] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
529 Tong HV, Hoan NX, Binh MT, Quyen DT, Meyer CG, Hang DTT, Hang DTD, Son HA, Van Luong H, Thuan ND, Giang NT, Quyet D, Bang MH, Song LH, Velavan TP, Toan NL. Upregulation of Enzymes involved in ISGylation and Ubiquitination in patients with hepatocellular carcinoma. Int J Med Sci 2020;17:347-53. [PMID: 32132870 DOI: 10.7150/ijms.39823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
530 Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther 2016;43:621-30. [PMID: 26784271 DOI: 10.1111/apt.13505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
531 Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-1244. [PMID: 26502405 DOI: 10.1038/ni.3290] [Cited by in Crossref: 141] [Cited by in F6Publishing: 130] [Article Influence: 23.5] [Reference Citation Analysis]
532 Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, Wang L, Huang X, Fu Q, Ye M, Zhang X, Chen Y, Ma C, Ge H, Wu J, Wei T, Chen Q, Yu C, Xiao Y, Feng X, Guo G, Liang T, Bai X. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019;68:2019-2031. [PMID: 31227589 DOI: 10.1136/gutjnl-2019-318912] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 32.5] [Reference Citation Analysis]
533 Kudo M. Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. Liver Cancer 2018;7:134-47. [PMID: 29888204 DOI: 10.1159/000484619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
534 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
535 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
536 Liu KC, Hao YH, Lv WF, Jia WD, Ji CS, Zhou CZ, Cheng DL, Xu SB, Gao ZG, Su MX, Shi CS. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:3461-8. [PMID: 32904650 DOI: 10.2147/DDDT.S248850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
537 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 22.7] [Reference Citation Analysis]
538 Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta. 2012;743:90-100. [PMID: 22882828 DOI: 10.1016/j.aca.2012.07.013] [Cited by in Crossref: 100] [Cited by in F6Publishing: 91] [Article Influence: 11.1] [Reference Citation Analysis]
539 Wang CH, Liu LL, Liao DZ, Zhang MF, Fu J, Lu SX, Chen SL, Wang H, Cai SH, Zhang CZ, Zhang HZ, Yun JP. PRAF2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Cancer Manag Res 2018;10:2241-8. [PMID: 30100755 DOI: 10.2147/CMAR.S166789] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
540 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19:8822-8830. [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
541 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
542 Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front Oncol 2019;9:1412. [PMID: 31921669 DOI: 10.3389/fonc.2019.01412] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
543 Chang TM, Hung WC. The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescence-like phenotype. Cancer Biol Ther 2013;14:222-9. [PMID: 23291986 DOI: 10.4161/cbt.23293] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
544 Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A, Linares JF, Reina-Campos M, Umemura S, Valasek MA, Seki E, Yamaguchi K, Koike K, Itoh Y, Diaz-Meco MT, Moscat J, Karin M. p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. Cancer Cell 2016;29:935-48. [PMID: 27211490 DOI: 10.1016/j.ccell.2016.04.006] [Cited by in Crossref: 212] [Cited by in F6Publishing: 205] [Article Influence: 42.4] [Reference Citation Analysis]
545 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834.ecollection] [Reference Citation Analysis]
546 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
547 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013;19:3207-16. [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
548 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018;8:4773. [PMID: 29555927 DOI: 10.1038/s41598-018-22923-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
549 Khattab M, Fouad M, Ahmed E. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol 2015;7:2474-81. [PMID: 26483869 DOI: 10.4254/wjh.v7.i23.2474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
550 Cai W, He B, Fan Y, Fang C, Jia F. Comparison of liver volumetry on contrast-enhanced CT images: one semiautomatic and two automatic approaches. J Appl Clin Med Phys 2016;17:118-27. [PMID: 27929487 DOI: 10.1120/jacmp.v17i6.6485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
551 Mohlman MK, Saleh DA, Ezzat S, Abdel-Hamid M, Korba B, Shetty K, Amr S, Loffredo CA. Viral transmission risk factors in an Egyptian population with high hepatitis C prevalence. BMC Public Health 2015;15:1030. [PMID: 26446713 DOI: 10.1186/s12889-015-2369-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
552 Feng D, Hui X, Shi-Chun L, Yan-Hua B, Li C, Xiao-Hui L, Jie-Yu Y. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget 2017;8:96649-55. [PMID: 29228559 DOI: 10.18632/oncotarget.20029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
553 Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol. 2014;20:15269-15274. [PMID: 25386075 DOI: 10.3748/wjg.v20.i41.15269] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
554 Sen S, Langiewicz M, Jumaa H, Webster NJ. Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology 2015;61:171-83. [PMID: 25132062 DOI: 10.1002/hep.27380] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
555 Issa D, Alkhouri N. Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history. Hepatobiliary Surg Nutr 2017;6:401-3. [PMID: 29312975 DOI: 10.21037/hbsn.2017.07.07] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
556 Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS, Baek MJ. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Res Treat. 2017;49:246-254. [PMID: 27456947 DOI: 10.4143/crt.2016.066] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
557 Wang W, Huang P, Wu P, Kong R, Xu J, Zhang L, Yang Q, Xie Q, Zhang L, Zhou X, Chen L, Xie H, Zhou L, Zheng S. BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis. Oncotarget 2015;6:20252-65. [PMID: 25970780 DOI: 10.18632/oncotarget.3857] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
558 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, He YJ, Lee YH, Huang YH, Hou MC, Huo TI. Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Sci Rep 2018;8:15074. [PMID: 30305679 DOI: 10.1038/s41598-018-33536-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
559 Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol 2017;2:98. [PMID: 29264436 DOI: 10.21037/tgh.2017.11.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
560 Jain D. Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S67-S73. [PMID: 25755614 DOI: 10.1016/j.jceh.2014.03.047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
561 Wang ST, Ho HJ, Lin JT, Shieh JJ, Wu CY. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8:e2626. [PMID: 28230855 DOI: 10.1038/cddis.2016.472] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 15.0] [Reference Citation Analysis]
562 Jiao J, Sanchez JI, Thompson EJ, Mao X, McCormick JB, Fisher-Hoch SP, Futreal PA, Zhang J, Beretta L. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. Int J Mol Sci 2021;22:7411. [PMID: 34299031 DOI: 10.3390/ijms22147411] [Reference Citation Analysis]
563 Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99-105. [PMID: 27741441 DOI: 10.1016/j.coviro.2016.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
564 Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3:732-736. [PMID: 27275318 DOI: 10.3889/oamjms.2015.111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
565 Amicone L, Citarella F, Cicchini C. Epigenetic regulation in hepatocellular carcinoma requires long noncoding RNAs. Biomed Res Int. 2015;2015:473942. [PMID: 25861629 DOI: 10.1155/2015/473942] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
566 Li D, Ding X, Xie M, Huang Z, Han P, Tian D, Xia L. CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis. Theranostics 2020;10:3749-66. [PMID: 32206120 DOI: 10.7150/thno.42596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
567 Teng Y, Radde BN, Litchfield LM, Ivanova MM, Prough RA, Clark BJ, Doll MA, Hein DW, Klinge CM. Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem 2015;290:15799-811. [PMID: 25969534 DOI: 10.1074/jbc.M115.641167] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
568 Cui Y, Wu X, Lin C, Zhang X, Ye L, Ren L, Chen M, Yang M, Li Y, Li M, Li J, Guan J, Song L. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway. Oncogene 2019;38:5516-29. [PMID: 30936461 DOI: 10.1038/s41388-019-0807-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
569 Hu M, Zhao L, Hu S, Yang J. The association between two common polymorphisms in MicroRNAs and hepatocellular carcinoma risk in Asian population. PLoS One. 2013;8:e57012. [PMID: 23437296 DOI: 10.1371/journal.pone.0057012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
570 Ren CX, Leng RX, Fan YG, Pan HF, Li BZ, Wu CH, Wu Q, Wang NN, Xiong QR, Geng XP, Ye DQ. Intratumoral and peritumoral expression of CD68 and CD206 in hepatocellular carcinoma and their prognostic value. Oncol Rep 2017;38:886-98. [PMID: 28656201 DOI: 10.3892/or.2017.5738] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
571 Chow AK, Yau SW, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020;11:589-605. [PMID: 32879846 DOI: 10.5306/wjco.v11.i8.589] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Shinoda K, Kuboki S, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Miyazaki M. Pin1 facilitates NF-κB activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer. 2015;113:1323-1331. [PMID: 26461058 DOI: 10.1038/bjc.2015.272] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
573 Wang J, Li H, Xia C, Yang X, Dai B, Tao K, Dou K. Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1. Onco Targets Ther 2019;12:869-82. [PMID: 30774374 DOI: 10.2147/OTT.S190061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
574 Hlady RA, Zhou D, Puszyk W, Roberts LR, Liu C, Robertson KD. Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer. Epigenetics. 2017;12:215-225. [PMID: 28059585 DOI: 10.1080/15592294.2016.1277297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
575 Li W, Yu J, Lian B, Sun H, Li J, Zhang M, Li L, Li Y, Liu Q, Xie L. Identifying prognostic features by bottom-up approach and correlating to drug repositioning. PLoS One 2015;10:e0118672. [PMID: 25738841 DOI: 10.1371/journal.pone.0118672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
576 Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2019;11:E1206. [PMID: 31430945 DOI: 10.3390/cancers11081206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
577 Parsons HM, Chu Q, Karlitz JJ, Stevens JL, Harlan LC. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. Liver Cancer 2017;6:216-26. [PMID: 29234628 DOI: 10.1159/000473862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
578 Song MA, Kwee SA, Tiirikainen M, Hernandez BY, Okimoto G, Tsai NC, Wong LL, Yu H. Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. Epigenetics. 2016;11:464-474. [PMID: 27248055 DOI: 10.1080/15592294.2016.1151586] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
579 Panebianco C, Saracino C, Pazienza V. Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression. Tumour Biol 2014;35:7307-15. [PMID: 24833096 DOI: 10.1007/s13277-014-2075-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
580 Chang CH, Chen SJ, Liu CY. Risk of Developing Depressive Disorders following Hepatocellular Carcinoma: A Nationwide Population-Based Study. PLoS One. 2015;10:e0135417. [PMID: 26295711 DOI: 10.1371/journal.pone.0135417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
581 Weintraub K. Vaccines: taking a shot at protection. Nature 2014;516:S12-3. [PMID: 25470194 DOI: 10.1038/516S12a] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
582 Yartel AK, Morgan RL, Rein DB, Ann Brown K, Kil NB, Massoud OI, Fallon MB, Smith BD. HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. Am J Prev Med 2015;49:423-7. [PMID: 25896194 DOI: 10.1016/j.amepre.2015.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
583 Lessel D, Vaz B, Halder S, Lockhart PJ, Marinovic-Terzic I, Lopez-Mosqueda J, Philipp M, Sim JC, Smith KR, Oehler J, Cabrera E, Freire R, Pope K, Nahid A, Norris F, Leventer RJ, Delatycki MB, Barbi G, von Ameln S, Högel J, Degoricija M, Fertig R, Burkhalter MD, Hofmann K, Thiele H, Altmüller J, Nürnberg G, Nürnberg P, Bahlo M, Martin GM, Aalfs CM, Oshima J, Terzic J, Amor DJ, Dikic I, Ramadan K, Kubisch C. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet 2014;46:1239-44. [PMID: 25261934 DOI: 10.1038/ng.3103] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 16.6] [Reference Citation Analysis]
584 Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A. Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus. Transl Oncol 2018;11:511-7. [PMID: 29524828 DOI: 10.1016/j.tranon.2018.02.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
585 Yuan S, Si W, Zhuang K, Li Y, Zhang Y, Liu J, Yang L, Zhang X. LncRNA UCID Promotes Hepatocellular Carcinoma Metastasis via Stabilization of Snail. Onco Targets Ther 2021;14:725-36. [PMID: 33536764 DOI: 10.2147/OTT.S277951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
586 Martín-Sierra C, Martins R, Coucelo M, Abrantes AM, Oliveira RC, Tralhão JG, Botelho MF, Furtado E, Domingues MR, Paiva A, Laranjeira P. Elevated soluble TNFα levels and upregulated TNFα mRNA expression in purified peripheral blood monocyte subsets associated with high-grade hepatocellular carcinoma. J Inflamm (Lond) 2020;17:14. [PMID: 32256215 DOI: 10.1186/s12950-020-00243-7] [Reference Citation Analysis]
587 Hung MH, Chen YL, Chen LJ, Chu PY, Hsieh FS, Tsai MH, Shih CT, Chao TI, Huang CY, Chen KF. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation. Cell Death Dis 2019;10:420. [PMID: 31142735 DOI: 10.1038/s41419-019-1646-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
588 Liu T, Liu D, Liu R, Jiang H, Yan G, Li W, Sun L, Zhang S, Liu Y, Guo K. Discovering potential serological biomarker for chronic Hepatitis B Virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis. Sci Rep 2017;7:38918. [PMID: 28079114 DOI: 10.1038/srep38918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
589 Kim B, Lee JH, Kim JK, Kim HJ, Kim YB, Lee D. The capsule appearance of hepatocellular carcinoma in gadoxetic acid-enhanced MR imaging: Correlation with pathology and dynamic CT. Medicine (Baltimore) 2018;97:e11142. [PMID: 29924016 DOI: 10.1097/MD.0000000000011142] [Cited by in Crossref: 11] [Article Influence: 3.7] [Reference Citation Analysis]
590 Karageorgos SA, Stratakou S, Koulentaki M, Voumvouraki A, Mantaka A, Samonakis D, Notas G, Kouroumalis EA. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Ann Gastroenterol 2017;30:357-63. [PMID: 28469367 DOI: 10.20524/aog.2017.0135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
591 Maegawa FB, Shehorn L, Aziz H, Kettelle J, Jie T, Riall TS. Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma. JAMA Netw Open 2019;2:e187142. [PMID: 30657533 DOI: 10.1001/jamanetworkopen.2018.7142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
592 Lee SY, Lee SH, Kim JE, Kim H, Kim K, Kook YH, Kim BJ. Identification of Novel A2/C2 Inter-Genotype Recombinants of Hepatitis B Virus from a Korean Chronic Patient Co-Infected with Both Genotype A2 and C2. Int J Mol Sci. 2017;18:pii: E737. [PMID: 28358313 DOI: 10.3390/ijms18040737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
593 Vogl TJ, Langenbach MC, Hammerstingl R, Albrecht MH, Chatterjee AR, Gruber-Rouh T. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial. Hepatol Int 2021;15:685-94. [PMID: 34043158 DOI: 10.1007/s12072-021-10193-8] [Reference Citation Analysis]
594 Xu J, An P, Winkler CA, Yu Y. Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets. Front Oncol. 2020;10:1271. [PMID: 32850386 DOI: 10.3389/fonc.2020.01271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
595 Wang C, Cigliano A, Jiang L, Li X, Fan B, Pilo MG, Liu Y, Gui B, Sini M, Smith JW, Dombrowski F, Calvisi DF, Evert M, Chen X. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Hepatology 2015;61:200-13. [PMID: 25145583 DOI: 10.1002/hep.27396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
596 Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. Oncotarget. 2017;8:15704-15715. [PMID: 28152517 DOI: 10.18632/oncotarget.14944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
597 Zhang ZF, Feng XS, Chen H, Duan ZJ, Wang LX, Yang D, Liu PX, Zhang QP, Jin YL, Sun ZG, Liu H. Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol 2016;16:57. [PMID: 27255554 DOI: 10.1186/s12876-016-0474-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
598 Van TM, Polykratis A, Straub BK, Kondylis V, Papadopoulou N, Pasparakis M. Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis. J Clin Invest 2017;127:2662-77. [PMID: 28628031 DOI: 10.1172/JCI92508] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
599 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
600 Teng L, Wang K, Liu Y, Ma Y, Chen W, Bi L. Based on Integrated Bioinformatics Analysis Identification of Biomarkers in Hepatocellular Carcinoma Patients from Different Regions. Biomed Res Int 2019;2019:1742341. [PMID: 31886176 DOI: 10.1155/2019/1742341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
601 Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology 2021;73:713-25. [PMID: 32383272 DOI: 10.1002/hep.31309] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 27.0] [Reference Citation Analysis]
602 Chen CC, Yeh HZ, Chang CS, Ko CW, Lien HC, Wu CY, Hung SW. Transarterial embolization of metastatic mediastinal hepatocellular carcinoma. World J Gastroenterol 2013;19:3512-6. [PMID: 23801848 DOI: 10.3748/wjg.v19.i22.3512] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
603 Sohn BH, Park IY, Shin JH, Yim SY, Lee JS. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells. Exp Mol Med 2018;50:e421. [PMID: 29303508 DOI: 10.1038/emm.2017.174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
604 Christou CD, Tooulias A, Tsolakidis A, Papayiannis V, Pianetcki-Tsiantzi B, Tsoulfas G, Papadopoulos VN. Management of Hepatocellular Carcinoma in the Era of Individualized Therapy: The Experience of a Greek Tertiary Center.Ochsner J. 2020;20:272-278. [PMID: 33071659 DOI: 10.31486/toj.19.0092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
605 Zhang JX, Li P, Chen Z, Lin H, Cai Z, Liao W, Pan Z. Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis. BMC Cancer 2020;20:556. [PMID: 32539768 DOI: 10.1186/s12885-020-07051-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
606 Wang K, Kievit FM, Sham JG, Jeon M, Stephen ZR, Bakthavatsalam A, Park JO, Zhang M. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Small 2016;12:477-87. [PMID: 26641029 DOI: 10.1002/smll.201501985] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
607 Lv X, Zhao F, Huo X, Tang W, Hu B, Gong X, Yang J, Shen Q, Qin W. Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma. Med Oncol 2016;33:70. [PMID: 27262566 DOI: 10.1007/s12032-016-0785-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
608 Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, Cai W, Cheng W, Liu SH, Cheng P, Cai Y, Rattray NJW, Johnson CH, Chen L, Cheng YC. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Sci Rep 2021;11:13482. [PMID: 34188068 DOI: 10.1038/s41598-021-91623-3] [Reference Citation Analysis]
609 Yang Y, Guo J, Hao Y, Wang F, Li F, Shuang S, Wang J. Silencing of karyopherin α2 inhibits cell growth and survival in human hepatocellular carcinoma. Oncotarget 2017;8:36289-304. [PMID: 28422734 DOI: 10.18632/oncotarget.16749] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
610 Pandit H, Li Y, Li X, Zhang W, Li S, Martin RCG. Enrichment of cancer stem cells via β-catenin contributing to the tumorigenesis of hepatocellular carcinoma. BMC Cancer 2018;18:783. [PMID: 30075764 DOI: 10.1186/s12885-018-4683-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
611 Mancini F, Giorgini L, Teveroni E, Pontecorvi A, Moretti F. Role of Sex in the Therapeutic Targeting of p53 Circuitry. Front Oncol 2021;11:698946. [PMID: 34307167 DOI: 10.3389/fonc.2021.698946] [Reference Citation Analysis]
612 Keane JT, Elangovan H, Stokes RA, Gunton JE. Vitamin D and the Liver-Correlation or Cause? Nutrients 2018;10:E496. [PMID: 29659559 DOI: 10.3390/nu10040496] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
613 Hoshida Y. Molecular Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2012;1:177-9. [PMID: 26213618 DOI: 10.1002/cld.117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
614 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016;7:242-55. [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
615 Huang S, Li C, Wang W, Li H, Sun Z, Song C, Li B, Duan S, Hu Y. A54 peptide-mediated functionalized gold nanocages for targeted delivery of DOX as a combinational photothermal-chemotherapy for liver cancer. Int J Nanomedicine 2017;12:5163-76. [PMID: 28790823 DOI: 10.2147/IJN.S131089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
616 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
617 Chedid MF, Scaffaro LA, Chedid AD, Maciel AC, Cerski CT, Reis MJ, Grezzana-Filho TJ, de Araujo A, Leipnitz I, Kruel CD, Alvares-da-Silva MR, Kruel CR. Transarterial Embolization and Percutaneous Ethanol Injection as an Effective Bridge Therapy before Liver Transplantation for Hepatitis C-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2016;2016:9420274. [PMID: 26819615 DOI: 10.1155/2016/9420274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
618 Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013;8:371-380. [PMID: 23662157 DOI: 10.2217/fvl.13.11] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 9.6] [Reference Citation Analysis]
619 Cigliano A, Pilo MG, Li L, Latte G, Szydlowska M, Simile MM, Paliogiannis P, Che L, Pes GM, Palmieri G, Sini MC, Cossu A, Porcu A, Vidili G, Seddaiu MA, Pascale RM, Ribback S, Dombrowski F, Chen X, Calvisi DF. Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget 2017;8:90638-50. [PMID: 29207593 DOI: 10.18632/oncotarget.21469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
620 Wang ZG, Zheng H, Gao W, Han J, Cao JZ, Yang Y, Li S, Gao R, Liu H, Pan ZY, Fu SY, Gu FM, Xing H, Ni JS, Yan HL, Ren H, Zhou WP. eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget 2016;7:62327-39. [PMID: 27694689 DOI: 10.18632/oncotarget.11469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
621 Yang Z, Liao X, Lu Y, Xu Q, Tang B, Chen X, Yu Y. Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2017;2017:3428253. [PMID: 28680448 DOI: 10.1155/2017/3428253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
622 Ma X, Cui Y, Zhou H, Li Q. Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients. Oncol Lett 2018;15:9110-6. [PMID: 29805642 DOI: 10.3892/ol.2018.8466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
623 Radwan HA, Hamed EH, Saleh OM. Significance of Serum Adiponectin and Insulin Resistance Levels in Diagnosis of Egyptian Patients with Chronic Liver Disease and HCC. Asian Pac J Cancer Prev 2019;20:1833-9. [PMID: 31244307 DOI: 10.31557/APJCP.2019.20.6.1833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
624 Jiang M, Wu N, Chen X, Wang W, Chu Y, Liu H, Li W, Chen D, Li X, Xu B. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease. J Int Med Res 2019;47:1453-66. [PMID: 30871397 DOI: 10.1177/0300060519833527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
625 Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumour Biol 2014;35:3647-56. [PMID: 24326769 DOI: 10.1007/s13277-013-1483-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
626 Li D, Fu J, Du M, Zhang H, Li L, Cen J, Li W, Chen X, Lin Y, Conway EM, Pikarsky E, Wang H, Pan G, Ji Y, Wang HY, Hui L. Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization. Hepatology 2016;64:1105-20. [PMID: 27177758 DOI: 10.1002/hep.28637] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
627 Fischer TD, Wang JH, Vlada A, Kim JS, Behrns KE. Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World J Hepatol 2014;6:752-8. [PMID: 25349646 DOI: 10.4254/wjh.v6.i10.752] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
628 Chang WT, Cheng HL, Hsieh BS, Chiu CC, Lee KT, Chang KL. Progesterone increases apoptosis and inversely decreases autophagy in human hepatoma HA22T/VGH cells treated with epirubicin. ScientificWorldJournal 2014;2014:567148. [PMID: 24971383 DOI: 10.1155/2014/567148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
629 Asai A, Tsuchimoto Y, Ohama H, Fukunishi S, Tsuda Y, Kobayashi M, Higuchi K, Suzuki F. Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC. Oncoimmunology 2017;6:e1299301. [PMID: 28507807 DOI: 10.1080/2162402X.2017.1299301] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
630 Malaguarnera M, Latteri S, Bertino G, Madeddu R, Catania VE, Currò G, Borzì AM, Drago F, Malaguarnera G. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. Clin Exp Gastroenterol 2018;11:373-80. [PMID: 30323642 DOI: 10.2147/CEG.S172663] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
631 Sun J, Jiang W, Tian D, Guo Q, Shen Z. Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression. Onco Targets Ther 2018;11:8227-37. [PMID: 30538492 DOI: 10.2147/OTT.S179844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
632 Ji J, Wang H, Li Y, Zheng L, Yin Y, Zou Z, Zhou F, Zhou W, Shen F, Gao C. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS One 2016;11:e0153227. [PMID: 27070780 DOI: 10.1371/journal.pone.0153227] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
633 Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma. Am J Pathol. 2016;186:242-247. [PMID: 26776075 DOI: 10.1016/j.ajpath.2015.10.003] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
634 Liao Y, Wei R, Yao R, Qin L, Li J, Yu J, Liao W. AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study. BMC Surg 2021;21:72. [PMID: 33536005 DOI: 10.1186/s12893-020-01037-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
635 Habs M, Binder K, Krauss S, Müller K, Ernst B, Valentini L, Koller M. A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Tea and Herbal Infusions. Nutrients 2017;9:E717. [PMID: 28686224 DOI: 10.3390/nu9070717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
636 Fan M, Qian N, Dai G. Expression and prognostic significance of doublecortin-like kinase 1 in patients with hepatocellular carcinoma. Oncol Lett 2017;14:7529-37. [PMID: 29344199 DOI: 10.3892/ol.2017.7082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
637 Gratte FD, Pasic S, Olynyk JK, Yeoh GCT, Tosh D, Coombe DR, Tirnitz-Parker JEE. Transdifferentiation of pancreatic progenitor cells to hepatocyte-like cells is not serum-dependent when facilitated by extracellular matrix proteins. Sci Rep 2018;8:4385. [PMID: 29531353 DOI: 10.1038/s41598-018-22596-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
638 Ezzikouri S, Benjelloun S, Pineau P. Human genetic variation and the risk of hepatocellular carcinoma development. Hepatol Int 2013;7:820-31. [PMID: 26201919 DOI: 10.1007/s12072-013-9463-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
639 Cwinn M, Walsh G, Rahman SH, Molinari M. The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes. Can J Gastroenterol Hepatol 2017;2017:9365657. [PMID: 28815170 DOI: 10.1155/2017/9365657] [Reference Citation Analysis]
640 Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One 2014;9:e115565. [PMID: 25531114 DOI: 10.1371/journal.pone.0115565] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
641 Fu CL, Pan B, Pan JH, Gan MF. Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma. Oncotarget 2017;8:33037-46. [PMID: 28380433 DOI: 10.18632/oncotarget.16521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
642 Cai H, Zheng Y, Wen Z, Yang Y, Yang S, Zhang Q. LncRNA AIRN influences the proliferation and apoptosis of hepatocellular carcinoma cells by regulating STAT1 ubiquitination. Arch Pharm Res 2021;44:414-26. [PMID: 33759138 DOI: 10.1007/s12272-021-01317-7] [Reference Citation Analysis]
643 Oliveira CP, Stefano JT, Carrilho FJ. Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatobiliary Surg Nutr 2017;6:350-2. [PMID: 29152487 DOI: 10.21037/hbsn.2017.06.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
644 Luo X, Feng GS. VEGFA genomic amplification tailors treatment of HCCs with sorafenib. Cancer Discov 2014;4:640-1. [PMID: 24891362 DOI: 10.1158/2159-8290.CD-14-0406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
645 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
646 Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013;43:51-64. [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 61] [Article Influence: 14.3] [Reference Citation Analysis]
647 Liem NT, Van Phong N, Kien NT, Anh BV, Huyen TL, Thao CT, Tu ND, Hiep DT, Hoai Thu DT, Nhung HTM. Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam. Int J Mol Sci 2019;20:E3166. [PMID: 31261712 DOI: 10.3390/ijms20133166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
648 Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T. Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. Mol Ther 2018;26:1840-54. [PMID: 29759938 DOI: 10.1016/j.ymthe.2018.04.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
649 Roth CG, Marzio DH, Guglielmo FF. Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs. Dig Dis Sci 2018;63:1102-22. [PMID: 29549474 DOI: 10.1007/s10620-018-4991-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
650 Luo T, Chen J, Liu JJ, Li H, You XM, Wang HL, Zhu SL, Li LQ. Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis. Onco Targets Ther 2016;9:4483-9. [PMID: 27499641 DOI: 10.2147/OTT.S108754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
651 Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P. Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: A protein-based hepatocellular carcinoma-associated study. Indian J Med Res 2018;147:361-8. [PMID: 29998871 DOI: 10.4103/ijmr.IJMR_1358_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
652 Yildiz G, Arslan-Ergul A, Bagislar S, Konu O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H, Erdal E. Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One. 2013;8:e64016. [PMID: 23691139 DOI: 10.1371/journal.pone.0064016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
653 Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle. 2013;12:1999-2010. [PMID: 23759595 DOI: 10.4161/cc.25099] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
654 Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer 2019;18:119. [PMID: 31324186 DOI: 10.1186/s12943-019-1046-7] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 44.0] [Reference Citation Analysis]
655 Yan F, Zheng Y, Huang L. Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma. Oncol Lett 2013;5:348-54. [PMID: 23255947 DOI: 10.3892/ol.2012.987] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
656 Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F, Vendemiale G, Serviddio G. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. United European Gastroenterol J. 2017;5:511-518. [PMID: 28588882 DOI: 10.1177/2050640616673516] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
657 Yang X, Ye X, Sun L, Gao F, Li Y, Ji X, Wang X, Feng Y, Wang X. Downregulation of serum RAB27B confers improved prognosis and is associated with hepatocellular carcinoma progression through PI3K-AKT-P21 signaling. Oncotarget 2017;8:61118-32. [PMID: 28977851 DOI: 10.18632/oncotarget.18010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
658 Han S, Zhang X, Zou L, Lu C, Zhang J, Li J, Li M. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One. 2014;9:e102686. [PMID: 25083860 DOI: 10.1371/journal.pone.0102686] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
659 Pang C, Huang G, Luo K, Dong Y, He F, Du G, Xiao M, Cai W. miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med 2017;6:2398-409. [PMID: 28940993 DOI: 10.1002/cam4.1188] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]